

Author Index

A

- Abdel-Baki A, Nicole L**
Schizophrénie et psychothérapies cognitivo-comportementales 511
- Adam K**
see West M (627)
- Adams SJ**
see Haslam D (559)
- Adams SJ, Pitre NL, Smith A**
Criminal harassment by patients with mental disorders 173
- Addington D**
see Grant C (746)
- Addington J**
see Grant C (746)
- Agostini M**
see Biancosino B (458)
- Ahmed AG, Heigh LM, Ramachandran KV**
Polydipsia, psychosis, and familial psychopathology 522
- Akçay F**
see Aydin N (658)
- Akiskal HS**
see Masi A (797)
- Al-Waneen R**
Neuroleptic malignant syndrome associated with quetiapine: a response [letter] 370
- Alvarez Tichauer GA**
see Bandelow B (948)
- Anaç A**
see Aydin N (658)
- Anderson J**
see Walter G (803)
- Arboleda-Flórez J**
Fugère R, Thompson-Cooper I, editors. *Breaking the chains: Bruno M Cormier and the McGill University Clinic in Forensic Psychiatry. Volume I, Tributes, Bruno M Cormier, MD (1919-1991)*. [book review] 179
see Stuart H (245)
- Asbury K**
see Plomin R (225)
- Association des psychiatres du Canada, Canadian Network for Mood and Anxiety Treatments**
Lignes directrices cliniques du traitement des troubles dépressifs 1S-92S
- Augustin R**
see Kumra S (923)
- Aydin N, Anaç A, Çayköylü A, Akçay F**
Reply: citalopram overdose, serotonin toxicity, or neuroleptic malignant syndrome? [letter] 658

B

- Bagby RM**
see Garfinkel PE (835)
- Ballon BC, Courbasson CMA, Smith PD**
Physical and sexual abuse issues among youths with substance use problems 617
- Bandelow B, Alvarez Tichauer GA, Späth C, Brooks A, Hajak G, Bleich S, Rütger E**
Separation anxiety and actual separation experiences during childhood in patients with panic disorder 948
- Baptista T, Lacruz A, Meza T, Contreras Q, Delgado C, Mejias MA, Hernández L**
Antipsychotic drugs and obesity: is prolactin involved? 829
- Barrett C**
see Sharma V (452)
- Bassarath L**
Neuroimaging studies of antisocial behaviour 728
Conduct disorder: a biopsychosocial review 609

Bassett AS

- Psychiatric genetics in the 21st century [editorial] 121
see Hodgkinson KA (123)
- Bassett AS, Chow EWC, Waterworth DM, Brzustowicz L**
Genetic insights into schizophrenia 131
- Basu D**
see Gupta N (862)
- Battacharyya S, Chaturvedi SK**
Metamorphosis of delusion of pregnancy [letter] 561
- Bebb RA**
see Morrison J (88)
- Benabarre A, Vieta E, Colom F, Martinez A, Reinares M, Corbella B**
Treatment of mixed mania with risperidone and mood stabilizers [letter] 866
- Benazzi F**
Is the minimum duration of hypomania in bipolar II disorder 4 days? [letter] 86
Quetiapine-associated hypomania in a woman with schizoaffective disorder [letter] 182
- Benjamin M**
Roberts N, Klin A, Volkmar F, Sparrow S, editors. *Asperger syndrome*. [book review] 366
- Bhopal JS**
St John's wort-induced sexual dysfunction [letter] 456
- Biancosino B, Grassi L**
Reply: atypical antipsychotics and neuroleptic malignant syndrome [letter] 866
- Biancosino B, Zanchi P, Agostini M, Grassi L**
Suspected neuroleptic catatonia induced by clozapine [letter] 458
- Biederman J**
see Tramontina S (941)
- Bilsbury C, Roach D, Bilsbury J**
Vanity as a psychological construct [letter] 760
- Bilsbury C, Tang M, Bilsbury J**
The phenomenology of perfectionism: "yumpity" [letter] 863
- Bilsbury J**
see Bilsbury C (760)
see Bilsbury C (863)
- Birmes P, Carreras D, Ducassé J-L, Charlet J-P, Warner BA, Lauque D, Laurent Schmitt L**
Peritraumatic dissociation, acute stress, and early posttraumatic stress disorder in victims of general crime 649
- Bissada H**
Mehler PS, Anderson AE, editors. *Eating disorders: a guide to medical care and complications*. [book review] 445
- Bizouard P**
see Loas G (850)
- Bland RC, Newman SC**
Mild dementia or cognitive impairment: the modified mini-mental state examination (3MS) as a screen for dementia 506
- Bleich S**
see Kropp S (457)
see Bandelow B (948)
- Bonin J-P**
see Lauzon S (841)
- Bonsack C**
see Lauzon S (841)
- Boon HS**
see Parker V (77)
- Boyer R**
see Vedantham K (149)
- Boyle MH**
see Lipman EL (657)
- Bradford JMW**
The neurobiology, neuropharmacology, and pharmacological treatment of the paraphilias and compulsive sexual behaviour 26

Author Index

A

- Abdel-Baki A, Nicole L**
Schizophrénie et psychothérapies cognitivo-comportementales 511
- Adam K**
see West M (627)
- Adams SJ**
see Haslam D (559)
- Adams SJ, Pitre NL, Smith A**
Criminal harassment by patients with mental disorders 173
- Addington D**
see Grant C (746)
- Addington J**
see Grant C (746)
- Agostini M**
see Biancosino B (458)
- Ahmed AG, Heigh LM, Ramachandran KV**
Polydipsia, psychosis, and familial psychopathology 522
- Akçay F**
see Aydin N (658)
- Akiskal HS**
see Masi A (797)
- Al-Waneen R**
Neuroleptic malignant syndrome associated with quetiapine: a response [letter] 370
- Alvarez Tichauer GA**
see Bandelow B (948)
- Anaç A**
see Aydin N (658)
- Anderson J**
see Walter G (803)
- Arboleda-Flórez J**
Fugère R, Thompson-Cooper I, editors. *Breaking the chains: Bruno M Cormier and the McGill University Clinic in Forensic Psychiatry. Volume I, Tributes, Bruno M Cormier, MD (1919-1991)*. [book review] 179
see Stuart H (245)
- Asbury K**
see Plomin R (225)
- Association des psychiatres du Canada, Canadian Network for Mood and Anxiety Treatments**
Lignes directrices cliniques du traitement des troubles dépressifs 1S-92S
- Augustin R**
see Kumra S (923)
- Aydin N, Anaç A, Çayköylü A, Akçay F**
Reply: citalopram overdose, serotonin toxicity, or neuroleptic malignant syndrome? [letter] 658

B

- Bagby RM**
see Garfinkel PE (835)
- Ballon BC, Courbasson CMA, Smith PD**
Physical and sexual abuse issues among youths with substance use problems 617
- Bandelow B, Alvarez Tichauer GA, Späth C, Brooks A, Hajak G, Bleich S, Rütger E**
Separation anxiety and actual separation experiences during childhood in patients with panic disorder 948
- Baptista T, Lacruz A, Meza T, Contreras Q, Delgado C, Mejias MA, Hernández L**
Antipsychotic drugs and obesity: is prolactin involved? 829
- Barrett C**
see Sharma V (452)
- Bassarath L**
Neuroimaging studies of antisocial behaviour 728
Conduct disorder: a biopsychosocial review 609

Bassett AS

- Psychiatric genetics in the 21st century [editorial] 121
see Hodgkinson KA (123)
- Bassett AS, Chow EWC, Waterworth DM, Brzustowicz L**
Genetic insights into schizophrenia 131
- Basu D**
see Gupta N (862)
- Battacharyya S, Chaturvedi SK**
Metamorphosis of delusion of pregnancy [letter] 561
- Bebb RA**
see Morrison J (88)
- Benabarre A, Vieta E, Colom F, Martinez A, Reinares M, Corbella B**
Treatment of mixed mania with risperidone and mood stabilizers [letter] 866
- Benazzi F**
Is the minimum duration of hypomania in bipolar II disorder 4 days? [letter] 86
Quetiapine-associated hypomania in a woman with schizoaffective disorder [letter] 182
- Benjamin M**
Roberts N, Klin A, Volkmar F, Sparrow S, editors. *Asperger syndrome*. [book review] 366
- Bhopal JS**
St John's wort-induced sexual dysfunction [letter] 456
- Biancosino B, Grassi L**
Reply: atypical antipsychotics and neuroleptic malignant syndrome [letter] 866
- Biancosino B, Zanchi P, Agostini M, Grassi L**
Suspected neuroleptic catatonia induced by clozapine [letter] 458
- Biederman J**
see Tramontina S (941)
- Bilsbury C, Roach D, Bilsbury J**
Vanity as a psychological construct [letter] 760
- Bilsbury C, Tang M, Bilsbury J**
The phenomenology of perfectionism: "yumpity" [letter] 863
- Bilsbury J**
see Bilsbury C (760)
see Bilsbury C (863)
- Birmes P, Carreras D, Ducassé J-L, Charlet J-P, Warner BA, Lauque D, Laurent Schmitt L**
Peritraumatic dissociation, acute stress, and early posttraumatic stress disorder in victims of general crime 649
- Bissada H**
Mehler PS, Anderson AE, editors. *Eating disorders: a guide to medical care and complications*. [book review] 445
- Bizouard P**
see Loas G (850)
- Bland RC, Newman SC**
Mild dementia or cognitive impairment: the modified mini-mental state examination (3MS) as a screen for dementia 506
- Bleich S**
see Kropp S (457)
see Bandelow B (948)
- Bonin J-P**
see Lauzon S (841)
- Bonsack C**
see Lauzon S (841)
- Boon HS**
see Parker V (77)
- Boyer R**
see Vedantham K (149)
- Boyle MH**
see Lipman EL (657)
- Bradford JMW**
The neurobiology, neuropharmacology, and pharmacological treatment of the paraphilias and compulsive sexual behaviour 26

Bradley E

see Lunskey Y (138)

Bristow K, Patten S

Using databases to prevent inpatient morbidity [letter] 455

Broocks A

see Bandelow B (948)

Brouillette MJ

Goldblum P, Erickson S. *Working with AIDS bereavement*. [book review] 363

Brownell MD, Yogendran MS

Attention-deficit hyperactivity disorder in Manitoba children: medical diagnosis and psychostimulant treatment rates 264

Brunet A

see Vedantham K (149)

Brzustowicz L

see Hodgkinson KA (123)

see Bassett AS (131)

Buckley PF, Miller DD, Singer B, Donenwirth K

The evolving clinical profile of atypical antipsychotic medications [letter] 285

Busnello ED

see Lara DR (371)

Buyukozturk A

see Sevinco L (68)

C**Callahan S**

see Chabrol H (847)

Cameron PM

Moore BE, Fine, BD, editors. *Psychoanalysis: the major concepts*. [book review] 856

Campbell B

see Crockford D (287)

Canadian Network for Mood and Anxiety Treatments

see Canadian Psychiatric Association (1S-92S)

Canadian Psychiatric Association, Canadian Network for Mood and Anxiety Treatments

Clinical guidelines for the treatment of depressive disorders 1S-92S

Carney S

see Geddes J (403)

Carreiras D

see Birnes P (649)

Carrey N

Developmental neurobiology: implications for pediatric psychopharmacology 810

Catoe KE

see Rowland AS (931)

Çayköylü A

see Aydın N (658)

Ceciarelli L

see Mancinelli I (862)

Chabrol H, Montovany A, Chouicha K, Callahan S, Mullet E

Frequency of borderline personality disorder in a sample of French high school students 847

Chalasani L, Kant R, KN Roy Chengappa KNR

Clozapine impact on clinical outcomes and aggression in severely ill adolescents with childhood-onset schizophrenia 965

Charlet J-P

see Birnes P (649)

Chartier M

see Sareen J (733)

Chaturvedi SK

see Battacharya S (561)

Chengappa KNR

see Chalasani L (965)

Chouicha K

see Chabrol H (847)

Chow WC

see Bassett AS (131)

Chue P, Welch R, Snaterse M

Combination risperidone and quetiapine therapy in refractory schizophrenia [letter] 86

Chue PS

see Tibbo P (144)

Using global assessment of functioning to evaluate an assertive community treatment program: reply [letter] 986

Clark C, Kopala L, Li DK, Hurwitz T

Regional cerebral glucose metabolism in never-medicated patients with schizophrenia 340

Cleghorn J

Sheinberg M, Fraenkel P. *The Relational trauma of incest: a family-based approach to treatment*. [book review] 757

Coccaro E

see Lee R (35)

Cole MG

see Ouimet M (819)

Collin K

see Hameer O (864)

Colom F

see Benabarre A (866)

Comparelli A

see Mancinelli I (862)

Conlon P

Re: Training residents for community psychiatric practice the resident perspective [letter] 561

Conn D

see Robillard M (764)

Contreras Q

see Baptista T (829)

Coodin S

Body mass index in persons with schizophrenia 549

Corbella B

see Benabarre A (866)

Corbière M

see Lauzon S (841)

Corcos M

see Loas G (850)

Corey J

Castle DJ, McGrath J, Kulkarni J, editors. *Women and Schizophrenia*. [book review] 652

Couper N

see Meza EE (167)

Courbasson CMA

see Ballon BC (617)

Cox BJ

see Wiebe J (418)

Crockford D, White WD, Campbell B

Gabapentin use in benzodiazepine dependence and detoxification [letter] 287

Cunningham JA

see Meza EE (167)

D**Dalfen AK, Devarajan S Stewart DE**

Who develops severe or fatal adverse drug reactions to selective serotonin reuptake inhibitors (SSRIs)? 258

Dassa D

see Noel-Jorand MC (761)

Dawson A

see Isbister GK (657)

Degner D

see Kropp S (457)

Delgado

see Baptista T (829)

Demidenko N

Bowles C. *If only you could read my mind: a guide to help couples understand each other and connect*. [book review] 858

Dereboy F

see Sevinco L (68)

Devarajan S

see Dursun SM (287)

Dewa CS, Hoch JS, Goering P

Using financial incentives to promote shared mental health care 488

Dewan VK

Re: Weight change with antipsychotic use [letter] 660

Dickens SE

see Garfinkel PE (835)

Dietrich DE

see Gödecke-Koch T (659)

Doiron JP, Nicki RM

Epidemiology of problem gambling in Prince Edward Island: a Canadian microcosm? 413

Donenwirth K

see Buckley PF (285)

Dongier M

Scarfone D. *Oublier Freud? Mémoire pour la psychanalyse*. [book review] 283

Evidence-based psychiatry: the pros and cons [editorial] 394

Dorian B

see Garfinkel PE (835)

Douglas S

see Labbate (182)

Ducassé J-L

see Birnes P (649)

Duffy A

Adolescents with psychiatric disorders: when to treat? And with what? [editorial] 795

Dunbar F

see Labelle A (534)

Dunn J

see Plomin R (225)

Durbin JF

see Tolomiczenko GS (253)

Dursun SM

Accelerated weight loss after treating refractory depression with fluoxetine plus topiramate: possible mechanisms of action? [letter] 287

E**Eizirik M**

see Tramontina S (941)

el-Guebaly N

see Meza EE (167)

Levin JD. *Primer for treating substance abusers*. [book review] 446

Elizur A

see Moldavsky D (562)

Emrich HM

see Kropp S (457)

Ensom MHH

see Hameer O (864)

Esplen MJ

see Maunder RG (622)

Étain B, Le Heuzey M-F, Mouren-Simeoni M-C

Electroconvulsivothérapie chez l'adolescent : considérations cliniques à propos d'une série d'observations 976

F**Faulk R**

see Rowland AS (931)

Faux P

Johnston CIM. *The father of Canadian psychiatry, Joseph Workman*. [book review] 656

Finch S

Sexual aversion disorder treated with behavioural desensitization [letter] 563

Fine J

Using language in psychiatry 916

Finlayson R

Denning P. *Practicing harm reduction psychotherapy: an alternative approach to addictions*. [book review] 365

Flament MF

see Loas G (850)

Francobandiera G

Olanzapine augmentation of serotonin uptake inhibitors in obsessive-compulsive disorder: an open study 356

Frankland A, Robinson MJ

Fatal chloral hydrate overdoses: unnecessary tragedies [letter] 763

Frick PJ

Effective interventions for children and adolescents with conduct disorder 597

Friedlander RB, Lazar S, Klancnik J

Atypical antipsychotic use in treating adolescents and young adults with developmental disabilities 741

Friedman EH

Neurobiology of the use of selective serotonin reuptake inhibitors during pregnancy [letter] 371

Frottier P

see Fruehwald S (763)

Fruehwald S, Reinhard E, Frottier P

What was the relevance of previous suicidal behaviour in prison suicides? [letter] 763

G**Gabriel A**

A case of resistant trichotillomania treated with risperidone-augmented fluvoxamine [letter] 285

Ganesan V, Kumar TCR, Khanna S

Obsessive compulsive disorder and psychosis 750

Garfinkel PE, Bagby RM, Schuller DR, Williams CC, Dickens SE, Dorian B

Predictors of success and satisfaction in the practice of psychiatry: a preliminary follow-up study 835

Garland EJ, Garland OM

Correlation between anxiety and oppositionality in a children's mood and anxiety disorder clinic 953

Garland OM

see Garland EJ (953)

Garlipp P

see Gödecke-Koch T (659)

Gates L

see Kusumakar V (959)

Geddes J, Carney S

Recent advances in evidence-based psychiatry 403

Gigante RA

see Lalonde JK (407)

Ginsberg DL, Sussman N

Gabapentin as a prophylaxis against steroid-induced mania [letter] 455

Girardi P

see Mancinelli I (862)

Girimaji SR

see Reddy PS (346)

Giudicelli S

see Noel-Jorand MC (761)

Gnam WH

The Contributions of health economics to mental health policy [editorial] 486

Gödecke-Koch T, Garlipp P, Haltenhof H, Dietrich DE

Lycanthropy: 2 case reports [letter] 659

Goering PN

see Tolomiczenko GS (253)

see Dewa CS (488)

Goldberg B

Gillberg C, O'Brien G, editors. *Developmental disability and behaviour*. [book review] 364

Grant C, Addington J, Addington D, Konnert C

Social functioning in first- and multipisode schizophrenia 746

Grassi L

see Biancosino B (458)

see Biancosino B (866)

Gray JE, O'Reilly RL

Clinically significant differences among Canadian mental health acts 315

Greben SE

Meissner WW. *Freud and psychoanalysis*. [book review] 859

Greenland C, Kajander R

In memoriam: John Douglas Morecroft Griffin 595

Grizenko N

see Zappitelli M (542)

Grof P

Watson D. *Mood and temperament*. [book review] 84

Keen E. *Chemicals for the mind: psychopharmacology and human consciousness*. [book review] 652

Jenicek M. *Clinical case reporting in evidence-based medicine*. [book review] 860

Barondes SH. *Mood Genes: Hunting for origins of mania and depression*. [book review] 983

Grunberg F

see Lesage AD (396)

Guelfi JD

see Loas G (850)

Gupta N

Venlafaxine-induced hypomanic switch in bipolar depression [letter] 760

Gupta N, Basu D

Does risperidone reduce concomitant substance abuse in cases of schizophrenia? [letter] 862

H**Haatainen K**

see Honkalampi K (373)

Haggarty J

see Husni M (183)

Hajak G

see Bandelow B (948)

Halfon O

see Loas G (850)

Halman MH

see Maggi JD (359)

Haltenhof H

see Gödecke-Koch T (659)

Hameer O, Collin K, Ensom MHH, Lomax S

Evaluation of droperidol in the acutely agitated child or adolescent [letter] 864

Hamuro A, Sugai Y, Isono H, Torii S

Clinical characteristics of delusional disorder [letter] 563

Harvey L

Davidson RT, Connor KM. *Herbs for the mind*. [book review] 447

Hasey G

Transcranial magnetic stimulation in the treatment of mood disorder: a review and comparison with electroconvulsive therapy 720

Haslam D, Adams S, Oluboka O

Re: The neurobiology, neuropharmacology, and pharmacologic treatment of paraphilias and compulsive sexual behaviour [letter] 559

Hazelton L

Person ES *The sexual century*. [book review] 177

Heigh LM

see Ahmed AG (522)

Hemsworth D

see Regehr C (156)

Hernández L

see Baptista T (829)

Hill J

see Regehr C (156)

Hintikka J

see Honkalampi K (373)

Hoaken PCS

Misleading drug advertising [letter] 660

Hoch JS

see Dewa CS (488)

Hodgkinson KA, Murphy J, O'Neill S, Brzustowicz L, Bassett AS

Genetic counselling for schizophrenia in the era of molecular genetics 123

Hogan K

see Karagianis J (370)

Honkalampi K, Tanskanen A, Hintikka J, Haatainen K, Viinamäki H

Does the cellular phone help to communicate when face-to-face contracts are difficult? [letter] 373

Howard AW

see Thompson AH (45)

Hudson JI

see Lalonde JK (407)

Hurwitz T

see Clark C (340)

Husni M, Koye N, Haggarty J

Severe anorexia in an Amish Mennonite teenager [letter] 183

I**Isbister GK, Dawson A, Whyte IM**

Citalopram overdose, serotonin toxicity, or neuroleptic malignant syndrome? [letter] 657

Isono H

see Hamuro A (563)

J**Jang KL, Vernon PA, Livesley WJ**

Behavioural genetic perspectives on personality function 234

Jeammot P

see Loas G (850)

Jerome L

Neurobiology of the use of selective serotonin reuptake inhibitors during pregnancy: response [letter] 452

Bupropion and drug-induced parkinsonism [letter] 560

Jin Y

see Thompson AH (45)

Joffe K

see Tibbo P (144)

Jones-Hiscock C, Roberts N

Silverman WK, Treffers PDA, editors. *Anxiety disorders in children and adolescents*. [book review] 982

Joseph LW

Charney DS, Nestler EJ, Bunney BS, editors. *Neurobiology of mental illness*. [book review] 180

Borod JC, editor. *The neuropsychology of emotion*. [book review] 557

Josiukas A

Heatherton TF, Kleck RE, Hebl MR, Hull JG, editors. *The social psychology of stigma*. [book review] 365

K**Kant R**

see Chalasani L (965)

Kapczinski F

see Machado-Vieira R (454)

Kapsan A

see Lerner V (441)

Karagianis J, Phillips L, Hogan K, LeDrew K

Neuroleptic malignant syndrome associated with quetiapine [letter] 370

Kato S

see Kobayashi T (89)

Keegan DL

Neuropsychopharmacology of pathological aggression and sexuality [editorial] 24

Kennedy SH

see McIntyre RS (273)

see McIntyre RS (322)

Kennedy NB

see Procyshyn RM (334)

Ketzer CR

see Tramontina S (941)

Khan SC

see Kusumakar V (959)

- Khanna S**
see Reddy PS (346)
see Raju GVL (372)
see Ganesan V (750)
- Kjernisted KD**
see Sareen J (733)
- Klancnik J**
see Friedlander RB (741)
- Kobayashi T, Okada Y, Nisijima K, Kato S**
"Internet delusion" in a patient with a schizoaffective disorder [letter] 89
- Konnert C**
see Grant C (746)
- Kopala L**
see Clark C (340)
- Koranyi EK**
Sadock BJ, Sadock VA, editors. *Kaplan & Sadock's comprehensive text-book of psychiatry*. 7th ed. [book review] 80
- Kotsopoulos S, Spivak M**
Obsessive-compulsive symptoms secondary to methylphenidate treatment [letter] 89
- Koye N**
see Husni M (183)
- Kropp S, Emrich HM, Bleich S, Degner D**
Olanzapine-related hyperglycemia in a nondiabetic woman [letter] 457
- Kumar S, Ng B**
Crowding and violence on psychiatric wards: explanatory models 433
- Kumar TCR**
see Raju GVL (372)
see Ganesan V (750)
- Kumra S, Shaw M, Merka P, Nakayama E, Augustin R**
Childhood-onset schizophrenia: research update 923
- Kusumakar V, MacMaster FP, Gates L, Sparkes SJ, Khan SC**
Left medial temporal cytosolic choline in early onset depression 959
- ## L
- Labbate LA, Douglas S**
Re: Treatment of posttraumatic stress disorder with olanzapine [letter] 182
- Labelle A, Light M, Dunbar F**
Risperidone Treatment of outpatients with schizophrenia: no evidence of sex differences in treatment response 534
- Lacruz A**
see Baptista T (829)
- Lalonde JK, Hudson JI, Gigante RA, Pope Jr HG**
Canadian and American psychiatrists' attitudes towards dissociative disorders diagnoses 407
- Lalonde P**
Villeneuve C, Toharia A. *La thérapie familiale apprivoisée*. [book review] 449
- Lancon C**
see Llorca P-M (87)
- Lang F**
see Loas G (850)
- Lara DR, Busnello ED, Souza DO**
Ondansetron rather than metoclopramide for bupropion-induced nausea [letter] 371
- Latimer EA**
Economic impacts of supported employment for persons with severe mental illness 496
- Lauque D**
see Birnes P (649)
- Laurent Schmitt L**
see Birnes P (649)
- Lauzon S, Corbière M, Bonin J-P, Bonsack C, Lesage AD, Ricard N**
Validation de la version française du health of the nation outcome scales (HoNOS-F) 841
- Lazanio S**
see Mancinelli I (862)
- Lazar S**
see Friedlander RB (741)
- Le Heuzey M-F**
see Étain B
- LeDrew K**
see Karagianis J (370)
- Lee R, Coccaro E**
The neuropsychopharmacology of criminality and aggression 35
- Lerner V, Kapsan A, Witzum E**
The misidentification of Clerambault's and Kandinsky-Clerambault's syndromes 441
- Lesage AD, Stip E, Grunberg F**
« What's up, doc? » Le contexte, les limites et les enjeux de la médecine fondée sur des données probantes pour les cliniciens (evidence-based medicine) 396
- Lesage AD**
see Lauzon S (841)
- Leung M**
see Morrison J (88)
- Levi D**
see Moldavsky D (562)
- Li DK**
see Clark C (340)
- Light M**
see Labelle A (534)
- Lipman EL, Secord M, Boyle MH**
Moving from the clinic to the community: the alone mothers together program [letter] 657
- Livesley WJ**
see Jang KL (234)
- Llorca P-M, Vaiva G, Lancon C**
Supersensitivity psychosis in patients with schizophrenia after sudden olanzapine withdrawal [letter] 87
- Loas G, Verrier A, Flament MF, Perez-Diaz F, Corcos M, Halfon O, Lang F, Bizouard P, Venisse J-L, Guelfi JD, Jeammet P**
Factorial structure of the sensation-seeking scale-form V: confirmatory factorial analyses in nonclinical and clinical samples 850
- Lomax S**
see Hameer O (864)
- Long S**
see Rowland AS (931)
- Luauté J-P, Saladini O**
Le concept français d'athymormie de 1922 à nos jours 639
- Lunskey Y, Bradley E**
Developmental disability training in Canadian psychiatry residency programs 138
- ## M
- Machado-Vieira R, Viale CI, Kapczinski F**
Mania associated with an energy drink: the possible role of caffeine, taurine, and inositol [letter] 454
- MacMaster FP**
see Kusumakar V (959)
- Maggi JD Halman MH**
The effect of divalproex sodium on viral load: a retrospective review of HIV-positive patients with manic syndromes 359
- Malla AM, Norman RMG**
Treating psychosis: is there more to early intervention than intervening early? 645
Re: using global assessment of functioning to evaluate an assertive community treatment program [letter] 986
- Mancinelli I, Ceciarelli L, Comparelli A, Lazanio S, Girardi P, Tatarelli R**
Suicide in adolescents in Italy (1969-1994) [letter] 862
- Mancini DA**
see McIntyre RS (322)
- Mansour-Robaey S, Robaey P**
Poirel C. *Le cerveau et la pensée : critique des fondements de la neuropsychologie*. [book review] 444
- Marmar CR**
see Vedantham K (149)

Marriage K, Petrie P, Worling D

Consumer satisfaction with an adolescent inpatient psychiatric unit 969

Martinez A

see Benabarre A (866)

Martins S

see Tramontina S (941)

Masi A, Toni C, Perugi G, Mucci M, Millepiedi S, Akiskal HS

Anxiety disorders in children and adolescents with bipolar disorder: a neglected comorbidity 797

Mauder RG, Esplen MJ

Supportive-expressive group psychotherapy for inflammatory bowel disease 622

Maziade M

see Roy M-A (52)

McCann SM

see McIntyre RS (273)

McIntyre RS, Mancini DA, Parikh S, Kennedy SH

Lithium revisited 322

McIntyre RS, McCann SM, Kennedy SH

Antipsychotic metabolic effects: weight gain, diabetes mellitus, and lipid abnormalities 273

Meier R

Berrios G, Hodges JR, editors. *Memory disorders in psychiatric practice*. [book review] 178

Mejias MA

see Baptista T (829)

Melamed Y

see Moldavsky D (562)

Mérette C

see Roy M-A (52)

Merino JG

Kaplan HI, Sadock BJ. *Kaplan & Sadock's synopsis of psychiatry and study guide and self-examination review on CD-ROM*. [book review] 81

Merka P

see Kumar S (923)

Metelitsa A

see Tibbo P (144)

Metzler TJ

see Vedantham K (149)

Meza EE, Cunningham JA, el-Guebaly N, Couper L

Alcoholism: beliefs and attitudes among Canadian alcoholism treatment practitioners 167

Meza T

see Baptista T (829)

Michalowski MB

see Tramontina S (941)

Millepiedi S

see Masi A (797)

Miller DD

see Buckley PF (285)

Moldavsky D, Szor H, Melamed Y, Levi D, Elizur A

Home visits from an outpatient psychiatric clinic [letter] 562

Montovany A

see Chabrol H (847)

Morrison J, Remick RA, Leung M, Wrixon KJ, Bebb RA

Galactorrhea induced by paroxetine [letter] 88

Mouren-Simeoni M-C

see Étain B

Mucci M

see Masi A (797)

Mullet E

see Chabrol H (847)

Murphy J

see Hodgkinson KA (123)

Myers M

New century: overcoming stigma, respecting differences [presidential address] 907

N**Naftel AJ**

see Rowland AS (931)

Nakayama E

see Kumar S (923)

Natarajan D

Re: developmental disability training in Canadian psychiatry residency programs [letter] 863

Newman SC

see Bland RC (506)

Ney P

Re: clinical guidelines for the treatment of depressive disorders [letter] 987

Ng B

see Kumar S (433)

Nicki RM

see Doiron JP (413)

Nicole L

see Abdel-Baki A (511)

Nisijima K

see Kobayashi T (89)

Noel-Jorand MC, Giudicelli S, Dassa D

Discourse characteristics of subjects with schizophrenia and prominent negative symptoms [letter] 761

Norman RMG

see Malla AM (645)

Norton J

The use of intravenous valproate in psychiatry [letter] 371

Laryngeal dystonia in psychiatry [letter] 453

O**O'Neill S**

see Hodgkinson KA (123)

O'Reilly RL

see Gray JE (315)

Okada Y

see Kobayashi T (89)

Oldfield R

see Patten SB (162)

Oluboka O

see Haslam D (559)

Ouimet MA, Primeau F, Cole MG

Psychosocial risk factors in poststroke depression: a systematic review 819

P**Pande S**

Everett B, Gallop R. *The link between childhood trauma and mental illness*. [book review] 984

Panke D

see Rowland AS (931)

Parikh S

see McIntyre RS (322)

Paris J

Why behavioural genetics is important for psychiatry [editorial] 223

Parker V, Remington G

Electroconvulsive therapy in cases of treatment-resistant psychosis [letter] 762

Parker V, Wong AHC, Boon HS, Seeman MV

Adverse reactions to St John's wort 77

Parker Z

Shaffer D, Lucas CP, Richters JE, editors. *Diagnostic assessment in child and adolescent psychopathology*. [book review] 654

Párraga HC, Párraga MI

Quetiapine treatment in patients with Tourette syndrome [letter] 184

Párraga MI

see Párraga HC (184)

Patten SB, Williams JVA, Petcu R, Oldfield R

Delirium in psychiatric inpatients: a case-control study 162

Patten SB

"Diet pills" and major depression in the Canadian population 438

see Wang J (422)

see Bristow K (455)

see Wang J (528)

see Wang J (632)

Perez-Diaz F

see Loas G (850)

Persad E

Electroconvulsive therapy: the controversy and the evidence [editorial] 702

Perugi G

see Masi A (797)

Petcu R

see Patten SB (162)

Petrie P

see Marriage K (969)

Phillips L

see Karagianis J (370)

Pinto T

see Zappitelli M (542)

Pitre NL

see Adams SJ (173)

Plomin R, Asbury K, Dunn J

Why are children in the same family so different? Nonshared environment a decade later 225

Pope Jr HG

see Lalonde JK (407)

Primeau F

see Ouimet MA (819)

Prior TI

Treatment of posttraumatic stress disorder with olanzapine [letter] 182

Procyshyn RM, Kennedy NB, Tse G, Thompson B

Antipsychotic polypharmacy: a survey of discharge prescriptions from a tertiary care psychiatric institution 334

R

Rabheru K

The use of electroconvulsive therapy in special patient populations 710

Rabiner D

see Rowland AS (931)

Rae-Grant Q

Change: chaos or challenge? [editorial] 22

Raju GVL, Ramesh Kumar TC, Khanna S

Sudden death following neuroleptic administration due to hemoperitoneum resulting from physical restraint [letter] 372

Ramachandran KV

see Ahmed AG (522)

Ravasia S

Risperidone-induced edema [letter] 453

Ravera G

see Vercellino F (559)

Rector NA

Friedman S, editor. *Cultural issues in the treatment of anxiety*. [book review] 82

Reddy PS, Reddy YCJ, Srinath S, Khanna S, Sheshadri SP, Girimaji SR

A family study of juvenile obsessive-compulsive disorder 346

Reddy YCJ

see Reddy PS (346)

Regehr C, Hemsworth D, Hill J

Individual predictors of posttraumatic distress: a structural equation model 156

Reichenfeld HF

What factors contribute to senior psychiatry residents' interest in geriatric psychiatry? [letter] 374

Reinares M

see Benabarre A (866)

Reinhard E

see Fruehwald S (763)

Remick RA

see Morrison J (88)

Remington G

see Parker V (762)

Ricard N

see Lauzon S (841)

Roach D

see Bilsbury C (760)

Robaey P

see Mansour-Robaey S (444)

Roberts N

Shamsie J, Nicholl S, Madsen KC. *Antisocial and violent youth*. [book review] 282

see Benjamin M (366)

Robillard M

Salzman C. *Psychiatric medications for older adults: the concise guide*. [book review] 756

Robillard M, Conn D

Gabapentin use in geriatric patients with depression and bipolar illness [letter] 764

Robinson GR

Steiner M, Yonkers KA, Eriksson E, editors. *Mood disorders in women*. [book review] 755

Robinson MJ

Antidepressant-induced sexual dysfunction in adolescent [letter] 185

Are newer antidepressants really "better tolerated"? [letter] 286

see Frankland A (763)

Roesch R

see Zapf PA (426)

Rohde L

see Tramontina S (941)

Rose S

see West M (627)

Rowland AS, Umbach DM, Catoe KE, Stallone L, Long S, Rabiner D, Naftel AJ, Panke D, Faulk R, Sandler DP

Studying the epidemiology of attention-deficit hyperactivity disorder: screening method and pilot results 931

Roy M-A, Mérette C, Maziade M I

Introduction à la psychiatrie génétique : progrès vers la découverte des gènes de susceptibilité aux troubles psychiatriques 52

Russell ML

see Wang J (528)

Rüther E

see Bandelow B (948)

S

Sakinofsky I

Maris RW, Berman AL, Silverman MM, editors. *Comprehensive textbook of suicidology*. [book review] 758

Saladini O

see Luauté J-P (639)

Sandler DP

see Rowland AS (931)

Sareen J, Chartier M, Kjernisted KD, Stein MB

Comorbidity of phobic disorders with alcoholism in a Canadian community sample 733

Sasseville M

Lamarre S. *Aider sans nuire: de la victimisation à la coopération*. [book review] 368

Schachar R

The science of child psychiatry [editorial] 915

Schuller DR

see Garfinkel PE (835)

Secord M

see Lipman EL (657)

Seeman MV

see Parker V (77)

Clinical trials in psychiatry: do results apply to practice? 352

Harrison PJ, Roberts GW, editors. *The neuropathology of schizophrenia: progress and interpretation*. [book review] 450

Sevincok L, Buyukozturk A, Dereboy F

Serum lipid concentrations in patients with comorbid generalized anxiety disorder and major depressive disorder 68

Shamsie J

Conduct disorder: a challenge to child psychiatry [editorial] 593

Sharma V, Barrett C

Tryptophan for treatment of rapid-cycling bipolar disorder comorbid with fibromyalgia [letter] 452

Sharma V

Electroconvulsive therapy's effect on suicide risk in patients with mood disorders 704

Shaw M

see Kumra S (923)

Sheshadri SP

see Reddy PS (346)

Singer B

see Buckley PF (285)

Smith A

see Adams SJ (173)

Smith PD

see Ballon BC (617)

Snaterse M

see Chue P (86)

Souza DO

see Lara DR (371)

Sparkes SJ

see Kusumakar V (959)

Späth C

see Bandelow B (948)

Spivak M

see Kotsopoulos S (89)

Spreng S

see West M (627)

Srinath S

see Reddy PS (346)

Stallone L

see Rowland AS (931)

Stein E

Raphael B, Wilson JP, editors. *Psychological debriefing: theory, practice and evidence*. [book review] 655

Stein MB

see Sareen J (733)

Steinberg PI

Gedo J. *Spleen and nostalgia: a life and work in psychoanalysis*. [book review] 367

Safran JD, Muran JC. *Negotiating the therapeutic alliance: a relational treatment guide*. [book review] 556

Gabbard GO. *Psychodynamic psychiatry in clinical practice*. [book review] 856

Stewart DE

see Dalfen AK (258)

Stip E

Besche-Richard C. *La psychopathologie cognitive*. [book review] 282

see Lesage AD (396)

Storm V

see Walter G (803)

Streiner DL

Regression toward the mean: its etiology, diagnosis, and treatment 72

Stuart H, Arboleda-Flórez J

Community attitudes toward people with schizophrenia 245

Sugai Y

see Hamuro A (563)

Sussman N

see Ginsberg DL (455)

Szor H

see Moldavsky D (562)

T**Tabarsi E**

see Zerjav-Lacombe S (328)

Tang M

see Bilsbury C (863)

Tanskanen A

see Honkalampi K (373)

Tatarelli R

see Mancinelli I (862)

Thompson AH, Howard AW, Jin Y

A social problem index for Canada 45

Thompson B

see Procyshyn RM (334)

Tibbo P, Joffe K, Chue P, Metelitsa A, Wright E

Global Assessment of Functioning following assertive community treatment in Edmonton, Alberta: a longitudinal study 144

Tolomiczenko GS, Goering PN, Durbin JF

Educating the public about mental illness and homelessness: a cautionary note 253

Toni C

see Masi A (797)

Torii S

see Hamuro A (563)

Tramontina S, Martins S, Michalowski MB, Ketzer CR, Eizirik M, Biederman J, Rohde LA

School dropout and conduct disorder in Brazilian elementary school students 941

Tse G

see Procyshyn RM (334)

Tyndel M

Koran LM. *Obsessive-compulsive and related disorders in adults: a comprehensive clinical guide*. [book review] 84

U**Umbach DM**

see Rowland AS (931)

V**Vaiva G**

see Llorca P-M (87)

Vedantham K, Brunet A, Boyer R, Weiss DS, Metzler TJ, Marmar CR

Posttraumatic stress disorder, trauma exposure, and the current health of Canadian bus drivers 149

Velamoor VR

Atypical antipsychotics and neuroleptic malignant syndrome [letter] 865

Veneselli E

see Vercellino F (559)

Venisse J-L

see Loas G (850)

Vercellino F, Zanotto E, Ravera G, Veneselli E

Open-label risperidone treatment of 6 children and adolescents with autism [letter] 559

Vernon PA

see Jang KL (234)

Verrier A

see Loas G (850)

Viale CI

see Machado-Vieira R (454)

Vieta E

see Benabarre A (866)

Viinamäki H

see Honkalampi K (373)

Viljoen JL

see Zapf PA (426)

W**Walter G, Wiltshire C, Anderson J, Storm V**

The pharmacologic treatment of the early phase of first-episode psychosis in youths 803

Wang J, Patten SB

A prospective study of sex-specific effects of major depression on alcohol consumption 422

Alcohol consumption and major depression: findings from a follow-up study 632

Wang J, Patten SB, Russell ML

Alternative medicine use by individuals with major depression 528

Waring T

Sharpe SA. *The ways we love: a developmental approach to treating couples*. [book review] 448

Warner BA

see Birnes P (649)

Waterworth DM

see Bassett AS (131)

Weiss DS

see Vedantham K (149)

Welch R

see Chue P (86)

West M, Adam K, Spreng S, Rose S

Attachment disorganization and dissociative symptoms in clinically treated adolescents 627

White WD

see Crockford D (287)

Whyte IM

see Isbister GK (657)

Wiebe J, Cox BJ

A profile of Canadian adults seeking treatment for gambling problems and comparisons with adults entering an alcohol treatment program 418

Wiens A

Kennedy GJ. *Geriatric mental health care: a treatment guide for health professionals*. [book review] 448

Williams CC

see Garfinkel PE (835)

Williams JVA

see Patten SB (162)

Wiltshire C

see Walter G (803)

Witztum E

see Lerner V (441)

Wong AHC

see Parker V (77)

Woodside DB

Lock J, LeGrange D, Agras WS, Dare C. *Treatment manual for anorexia nervosa: a family-based approach*. [book review] 859

Woogh C

Is schizophrenia on the decline in Canada? 61

Worling D

see Marriage K (969)

Wright E

see Tibbo P (144)

Wrixon KJ

see Morrison J (88)

Y**Yogendran MS**

see Brownell MD (264)

Z**Zanchi P**

see Biancosino B (458)

Zanotto E

see Vercellino F (559)

Zapf PA, Roesch R, Viljoen JL

Assessing fitness to stand trial: the utility of the fitness interview test (revised edition) 426

Zappitelli M, Pinto T, Grizenko N

Pre-, peri-, and postnatal trauma in subjects with attention-deficit hyperactivity disorder 542

Zerjav-Lacombe S, Tabarsi E

Lamotrigine: A review of clinical studies in bipolar disorders 328

Subject Index

A

Absenteeism

School dropout and conduct disorder in Brazilian elementary school students (Tramontina S, Martins S, Michalowski MB, Ketzer CR, Eizirik M, Biederman J, Rohde LA) 941

acute psychiatric wards

Crowding and violence on psychiatric wards: explanatory models (Kumar S, Ng B) 433

acute stress

Peritraumatic dissociation, acute stress, and early posttraumatic stress disorder in victims of general crime (Birmes P, Carreras D, Ducassé J-L, Charlet J-P, Warner BA, Lauque D, Laurent Schmitt L) 649

addictions

Physical and sexual abuse issues among youths with substance use problems (Ballon BC, Courbasson CMA, Smith PD) 617

administration de la santé

« What's up, doc? » Le contexte, les limites et les enjeux de la médecine fondée sur des données probantes pour les cliniciens (evidence-based medicine) (Lesage AD, Stip E, Grunberg F) 396

adolescence

Antidepressant-induced sexual dysfunction in adolescent [letter] (Robinson MJ) 185

The pharmacologic treatment of the early phase of first-episode psychosis in youths (Walter G, Wiltshire C, Anderson J, Storm V) 803

Frequency of borderline personality disorder in a sample of French high school students (Chabrol H, Montovany A, Chouicha K, Callahan S, Mullet E) 847

adolescent

Evaluation of droperidol in the acutely agitated child or adolescent [letter] (Hameer O, Collin K, Ensom MHH, Lomax S) 864

Left medial temporal cytosolic choline in early onset depression (Kusumakar V, MacMaster FP, Gates L, Sparkes SJ, Khan SC) 959

Électroconvulsivothérapie chez l'adolescent : considérations cliniques à propos d'une série d'observations (Étain B, Le Heuzey M-F, Mouren-Simeoni M-C) 976

adolescent psychiatric inpatient unit

Consumer satisfaction with an adolescent inpatient psychiatric unit (Marriage K, Petrie P, Worling D) 969

adolescents

A family study of juvenile obsessive-compulsive disorder (Reddy PS, Reddy YCJ, Srinath S, Khanna S, Sheshadri SP, Girimaji SR) 346

Open-label risperidone treatment of 6 children and adolescents with autism [letter] (Vercellino F, Zanotto E, Ravera G, Veneselli E) 559

The use of electroconvulsive therapy in special patient populations (Raheru K) 710

Atypical antipsychotic use in treating adolescents and young adults with developmental disabilities (Friedlander RB, Lazar S, Klancnik J) 741

Adolescents with psychiatric disorders: when to treat? And with what? [editorial] Duffy A 795

Suicide in adolescents in Italy (1969-1994) [letter] (Mancinelli I, Ceciarelli L, Comparelli A, Laziano S, Girardi P, Tatarelli R) 862

adoption

Why are children in the same family so different? Nonshared environment a decade later (Plomin R, Asbury K, Dunn J) 225

adverse drug reaction

Adverse reactions to St John's wort (Parker V, Wong AHC, Boon HS, Seeman MV) 77

Who develops severe or fatal adverse drug reactions to selective serotonin reuptake inhibitors (SSRIs)? (Dalfen AK, Devarajan S, Stewart DE) 258

aggression

The neuropsychopharmacology of criminality and aggression (Lee R) 35

Clozapine impact on clinical outcomes and aggression in severely ill adolescents with childhood-onset schizophrenia (Chalasani L, Kant R, KN Roy Chengappa KNR) 965

agoraphobia

Separation anxiety and actual separation experiences during childhood in patients with panic disorder (Bandelow B, Alvarez Tichauer GA, Späth C, Broocks A, Hajak G, MD5, Bleich S, Rüther E) 948

AIDS

The effect of divalproex sodium on viral load: a retrospective review of HIV-positive patients with manic syndromes (Maggi JD, Halman MH) 359

alcohol abuse

Polydipsia, psychosis, and Familial Psychopathology (Ahmed AG, Heigh LM, Ramachandran KV) 522

Comorbidity of phobic disorders with alcoholism in a Canadian community sample (Sareen J, Chartier M, Kjemistad KD, Stein MB) 733

alcohol consumption

A prospective study of sex-specific effects of major depression on alcohol consumption (Wang J, Patten SB) 422

Alcohol consumption and major depression: findings from a follow-up study (Wang J, Patten SB) 632

alcoholism

A social problem index for Canada (Thompson AH, Howard AW, Jin Y) 45

Comorbidity of phobic disorders with alcoholism in a Canadian community sample (Sareen J, Chartier M, Kjemistad KD, Stein MB) 733

alternative medicine

Alcoholism: beliefs and attitudes among Canadian alcoholism treatment practitioners (Meza EE, Cunningham JA, el-Guebaly N, Couper L) 167

Alternative medicine use by individuals with major depression (Wang J, Patten SB, Russell ML) 528

amygdala

Left medial temporal cytosolic choline in early onset depression (Kusumakar V, MacMaster FP, Gates L, Sparkes SJ, Khan SC) 959

anorexia

Severe anorexia in an Amish Mennonite teenager [letter] (Husni M, Koye N, Haggarty J) 183

antiandrogens

The neurobiology, neuropharmacology, and pharmacological treatment of the paraphilias and compulsive sexual behaviour (Bradford JMW) 26

antidepressant

Adverse reactions to St John's wort (Parker V, Wong AHC, Boon HS, Seeman MV) 77

antidepressants

Clinical guidelines for the treatment of depressive disorders [supplement] (The Canadian Psychiatric Association, Canadian Network for Mood and Anxiety Treatments) 1S-92S

Antidepressant-induced sexual dysfunction in adolescent [letter] (Robinson MJ) 185

Are newer antidepressants really "better tolerated"? [letter] (Robinson MJ) 286

antidépresseurs

Lignes directrices cliniques du traitement des troubles dépressifs (Association des psychiatres du Canada, Canadian Network for Mood and Anxiety Treatments) 1S-92S

antipsychotics

Antipsychotic polypharmacy: a survey of discharge prescriptions from a tertiary care psychiatric institution (Procysyn RM, Kennedy NB, Tse G, Thompson B) 334

Risperidone Treatment of Outpatients With Schizophrenia: No Evidence of Sex Differences in Treatment Response (Labelle A, Light M, Dunbar F) 534

Re: weight change with antipsychotic use [letter] (Dewan VK) 660

antisocial behaviour

Effective interventions for children and adolescents with conduct disorder (Frick PJ) 597

Neuroimaging studies of antisocial behaviour (Bassarath L) 728

anxiety

Comorbidity of phobic disorders with alcoholism in a Canadian community sample (Sareen J, Chartier M, Kjemistad KD, Stein MB) 733

anxiety disorders

Anxiety disorders in children and adolescents with bipolar disorder: a neglected comorbidity (Masi A, Toni C, Perugi G, Mucci M, Millepiedi S, Akiskal HS) 797

appetite suppressants

"Diet pills" and major depression in the Canadian population (Patten SB) 438

aspects culturels

Lignes directrices cliniques du traitement des troubles dépressifs (Association des psychiatres du Canada, Canadian Network for Mood and Anxiety Treatments) 1S-92S

assertive community treatment

Global assessment of functioning following assertive community treatment in Edmonton, Alberta: a longitudinal study (Tibbo P, Joffe K, Chue P, Metelitsa A, Wright E) 144

Re: using global assessment of functioning to evaluate an assertive community treatment program [letter] (Malla A) 986

Using global assessment of functioning to evaluate an assertive community treatment program: reply [letter] (Chue PS) 986

athymhormie

Le concept français d'athymhormie de 1922 à nos jours (Luauté J-P, Saladini O) 639

attachment

Individual predictors of posttraumatic distress: a structural equation model (Regehr C, Hemsworth D, Hill J) 156

attention-deficit hyperactivity disorder

Attention-deficit hyperactivity disorder in Manitoba children: medical diagnosis and psychostimulant treatment rates (Brownell MD, Yogendran MS) 264

Pre-, peri-, and postnatal trauma in subjects with attention-deficit hyperactivity disorder (Zappitelli M, Pinto T, Grizenko N) 542

Studying the epidemiology of attention-deficit hyperactivity disorder: screening method and pilot results (Rowland AS, Umbach DM, Catoe KE, Stallone L, Long S, Rabiner D, Naftel AJ, Panke D, Faulk R, Sandler DP) 931

attitudes

Educating the public about mental illness and homelessness: a cautionary note (Tolomiczenko GS, Goering PN, Durbin JF) 253

atypical antipsychotics

Antipsychotic metabolic effects: weight gain, diabetes mellitus, and lipid abnormalities (McIntyre RS, McCann SM, Kennedy SH) 273

Atypical antipsychotics and neuroleptic malignant syndrome [letter] (Vela-moor VR) 865

Reply: atypical antipsychotics and neuroleptic malignant syndrome [letter] (Biancosino B, Grassi L) 866

The evolving clinical profile of atypical antipsychotic medications [letter] (Buckley PF, Miller DD, Singer B, Donenwirth K) 285

atypical neuroleptics

Atypical antipsychotic use in treating adolescents and young adults with developmental disabilities (Friedlander RB, Lazar S, Klancnik J) 741

augmentation

Lithium revisited (McIntyre RS, Mancini DA, Parikh S, Kennedy SH) 322

autism

Open-label risperidone treatment of 6 children and adolescents with autism [letter] (Vercellino F, Zanoatto E, Ravera G, Veneselli E) 559

B**behavioural desensitization**

Sexual aversion disorder treated with behavioural desensitization [letter] (Finch S) 563

behavioural genetics

Why behavioural genetics is important for psychiatry [editorial] (Paris J) 223

Why are children in the same family so different? Nonshared environment a decade later (Plomin R, Asbury K, Dunn J) 225

benzodiazepine

Gabapentin use in benzodiazepine dependence and detoxification [letter] (Crockford D, White WD, Campbell B) 287

biological treatment

Clinical guidelines for the treatment of depressive disorders [supplement] (The Canadian Psychiatric Association, Canadian Network for Mood and Anxiety Treatments) 1S-92S

bipolar depression

Venlafaxine-induced hypomanic switch in bipolar depression [letter] (Gupta N) 760

bipolar disorder

Lithium revisited (McIntyre RS, Mancini DA, Parikh S, Kennedy SH) 322

Lamotrigine: a review of clinical studies in bipolar disorders (Zerjav-Lacombe S, Tabarsi E) 328

Tryptophan for treatment of rapid-cycling bipolar disorder comorbid with fibromyalgia [letter] (Sharma V, Barrett C) 452

Anxiety disorders in children and adolescents with bipolar disorder: a neglected comorbidity (Masi A, Toni C, Perugi G, Mucci M, Millepiedi S, Akiskal HS) 797

The pharmacologic treatment of the early phase of first-episode psychosis in youths (Walter G, Wiltshire C, Anderson J, Storm V) 803

bipolar illness

Gabapentin use in geriatric patients with depression and bipolar illness [letter] (Robillard M, Conn D) 764

blended payments

Using financial incentives to promote shared mental health care (Dewa CS, Hoch JS, Goering P) 488

body mass index

Body mass index in persons with schizophrenia (Coodin S) 549

book review, addictions, psychotherapy

Denning P. *Practicing harm reduction psychotherapy: an alternative approach to addictions*. Finlayson R 365

book review, anxiety disorders

Koran LM. *Obsessive-compulsive and related disorders in adults: a comprehensive clinical guide*. Tyndel M 84

book review, child psychiatry

Gillberg C, O'Brien G, editors. *Developmental disability and behaviour*. Goldberg B 364

Roberts N, Klin A, Volkmar F, Sparrow S, editors. *Asperger syndrome*. Benjamin M 366

Shaffer D, Lucas CP, Richters JE, editors. *Diagnostic assessment in child and adolescent psychopathology*. Parker Z 654

Silverman WK, Treffers PDA, editors. *Anxiety disorders in children and adolescents*. Jones-Hiscock C, Roberts N 982

Everett B, Gallop R. *The link between childhood trauma and mental illness*. Pande S 984

book review, child and adolescent psychiatry

Shamsie J, Nicholl S, Madsen KC. *Antisocial and violent youth*. Roberts N 282

book review, eating disorders

Mehler PS, Anderson AE, editors. *Eating disorders: a guide to medical care and complications*. Bissada H 445

Lock J, LeGrange D, Agras WS, Dare C. *Treatment manual for anorexia nervosa: a family-based approach*. Woodside DB 859

book review, forensic psychiatry

Fugère R, Thompson-Cooper I, editors. *Breaking the chains: Bruno M Cormier and the McGill University Clinic in Forensic Psychiatry. Volume I, Tributes, Bruno M Cormier, MD (1919-1991)*. Arboleda-Flórez J 179

book review, general psychiatry

Sadock BJ, Sadock VA, editors. *Kaplan & Sadock's comprehensive textbook of psychiatry. 7th ed.* Koranyi EK 80

Kaplan HI, Sadock BJ. *Kaplan & Sadock's synopsis of psychiatry and study guide and self-examination review on CD-ROM*. Merino JG 81

Berrios G, Hodges JR, editors. *Memory disorders in psychiatric practice*. Meier R 178

Goldblum P, Erickson S. *Working with AIDS bereavement*. Brouillette MJ 363

Heatherton TF, Kleck RE, Hebl MR, Hull JG, editors. *The social psychology of stigma*. Josiukas A 365

Raphael B, Wilson JP, editors. *Psychological debriefing: theory, practice and evidence*. Stein E 655

Jenicek M. *Clinical case reporting in evidence-based medicine*. Grof 860

book review, geriatric psychiatry

Kennedy GJ. *Geriatric mental health care: a treatment guide for health professionals*. Wiens A 448

book review, geriatrics

Salzman C. *Psychiatric medications for older adults: the concise guide*. Robillard M 756

book review, history of psychiatry

Johnston CIM. *The father of Canadian psychiatry*. Joseph Workman. Faux P 656

book review, la psychanalyse

Scarfone D. *Oublier Freud? Mémoire pour la psychanalyse*. Dongier M 283

book review, mood disorders

Watson D. *Mood and temperament*. Grof P 84

Borod JC, editor. *The neuropsychology of emotion*. Joseph LW 557

book review, mood disorders, gender, sex

Steiner M, Yonkers KA, Eriksson E, editors. *Mood disorders in women*. Robinson GR 755

book review, mood disorders, genetics

Barondes SH. *Mood Genes: Hunting for origins of mania and depression*. Grof P 861

book review, neurobiology, basic science

Charney DS, Nestler EJ, Bunney BS, editors. *Neurobiology of mental illness*. Joseph L 180

book review, psychiatrie générale

Lamarre S. *Aider sans nuire: de la victimisation à la coopération*. Sas-seville M 368

Poirel C. *Le cerveau et la pensée: critique des fondements de la neuropsychologie*. Mansour-Robaey S, Robaey P 444

book review, psychiatric genetics

Faraone SV, Tsuang MT, Tsuang DWT. *Genetics of mental disorders, a guide for students, clinicians and researchers*. Grof P 983

book review, psychoanalysis

Gedo J. *Spleen and nostalgia: a life and work in psychoanalysis*. Steinberg PI 367

book review, psychopathologie cognitive

Besche-Richard C. *La psychopathologie cognitive*. Stip E 282

book review, psychopharmacology

Davidson RT, Connor KM. *Herbs for the mind*. Harvey L 447

Keen E. *Chemicals for the mind: psychopharmacology and human consciousness*. Grof P 652

book review, psychotherapy

Sharpe SA. *The ways we love: a developmental approach to treating couples*. Waring T 448

Safran JD, Muran JC. *Negotiating the therapeutic alliance: a relational treatment guide*. Steinberg PI 556

Moore BE, Fine, BD, editors. *Psychoanalysis: the major concepts*. Cameron PM 856

Gabbard GO. *Psychodynamic psychiatry in clinical practice*. Steinberg PI 856

book review, psychotherapy: family

Sheinberg M, Fraenkel P. *The relational trauma of incest: a family-based approach to treatment*. Cleghorn J 757

book review, psychotherapy: individual

Meissner WW. *Freud and psychoanalysis*. Greben SE 859

book review, psychotherapy: marital

Bowles C. *If only you could read my mind: a guide to help couples understand each other and connect*. Demidenko N 858

book review, psychotherapy, gender issues

Person ES. *The sexual century*. Hazelton L 177

book review, schizophrenia

Harrison PJ, Roberts GW, editors. *The neuropathology of schizophrenia: progress and interpretation*. Seeman MV 450

Castle DJ, McGrath J, Kulkarni J, editors. *Women and schizophrenia*. Corey J 652

book review, substance abuse

Levin JD. *Primer for treating substance abusers*. el-Guebaly N 446

book review, suicide

Maris RW, Berman AL, Silverman MM, editors. *Comprehensive textbook of suicidology*. Sakinofsky I 758

book review, thérapie familiale

Villeneuve C, Toharia A. *La Thérapie familiale apprivoisée*. Lalonde P 449

book review, transcultural psychiatry

Friedman S, editor. *Cultural issues in the treatment of anxiety*. Rector NA 82

borderline personality disorder

Frequency of borderline personality disorder in a sample of French high school students (Chabrol H, Montovany A, Chouicha K, Callahan S, Mullet E) 847

brain tumours

The use of electroconvulsive therapy in special patient populations (Rabheru K) 710

bupropion

Ondansetron rather than metoclopramide for bupropion-induced nausea [letter] (Lara DR, Busnello ED, Souza DO) 371

Bupropion and Drug-Induced Parkinsonism [letter] (Jerome L) 560

bus drivers

Posttraumatic stress disorder, trauma exposure, and the current health of Canadian bus drivers (Vedantham K, Brunet A, Boyer R, Weiss DS, Metzler TJ, Marmar CR) 149

C**caffeine**

Mania associated with an energy drink: the possible role of caffeine, taurine, and inositol [letter] (Machado-Vieira R, Viale CI, Kapczynski F) 454

capitation

Using financial incentives to promote shared mental health care (Dewa CS, Hoch JS, Goering P) 488

cardiovascular disease

Who develops severe or fatal adverse drug reactions to selective serotonin reuptake inhibitors (SSRIs)? (Dalfen AK, Devarajan S, Stewart DE) 258

catatonie

Électroconvulsivothérapie chez l'adolescent: considérations cliniques à propos d'une série d'observations (Étain B, Le Heuzey M-F, Mouren-Simeoni M-C) 976

cellular phone

Does the cellular phone help to communicate when face-to-face contracts are difficult? [letter] (Honkalampi K, Tanskanen A, Hintikka J, Haatainen K, Viinamäki H) 373

cerebral glucose metabolism

Regional cerebral glucose metabolism in never-medicated patients with schizophrenia (Clark C, Kopala L, Li DK, Hurwitz T) 340

change

Change: chaos or challenge? [editorial] (Rae-Grant Q) 22

change scores

Regression toward the mean: its etiology, diagnosis, and treatment (Streiner DL) 72

child

Evaluation of droperidol in the acutely agitated child or adolescent [letter] (Hameer O, Collin K, Ensom MHH, Lomax S) 864

child psychiatry

Conduct disorder: a challenge to child psychiatry [editorial] (Shamsie J) 593

The science of child psychiatry [editorial] (Schachar R) 915

childhood anxiety disorders

Correlation between anxiety and oppositionality in a children's mood and anxiety disorder clinic (Garland EJ, Garland OM) 953

childhood-onset schizophrenia

Clozapine impact on clinical outcomes and aggression in severely ill adolescents with childhood-onset schizophrenia (Chalasani L, Kant R, KN Roy Chengappa KNR) 965

children

A family study of juvenile obsessive-compulsive disorder (Reddy PS, Reddy YCJ, Srinath S, Khanna S, Sheshadri SP, Girimaji SR) 346

Open-label risperidone treatment of 6 children and adolescents with autism [letter] (Vercellino F, Zanotto E, Ravera G, Veneselli E) 559

The use of electroconvulsive therapy in special patient populations (Rabheru K) 710

Studying the epidemiology of attention-deficit hyperactivity disorder: screening method and pilot results (Rowland AS, Umbach DM, Catoe KE,

Stallone L, Long S, Rabiner D, Nafiei AJ, Panke D, Faulk R, Sandler DP) 931

Childhood-onset schizophrenia: research update (Kumra S, Shaw M, Merka P, Nakayama E, Augustin R) 923

children and adolescents

Clinical guidelines for the treatment of depressive disorders [supplement] (The Canadian Psychiatric Association, Canadian Network for Mood and Anxiety Treatments) 1S-92S

chloral hydrate

Fatal chloral hydrate overdoses: unnecessary tragedies [letter] (Frankland A, Robinson MJ) 763

cholesterol

Serum lipid concentrations in patients with comorbid generalized anxiety disorder and major depressive disorder (Sevincok L, Buyukozturk A, Dereboy F) 68

choline

Left medial temporal cytosolic choline in early onset depression (Kusumakar V, MacMaster FP, Gates L, Sparkes SJ, Khan SC)

chronic depression

Clinical guidelines for the treatment of depressive disorders [supplement] (The Canadian Psychiatric Association, Canadian Network for Mood and Anxiety Treatments) 1S-92S

chronic mentally ill

Global assessment of functioning following assertive community treatment in Edmonton, Alberta: a longitudinal study (Tibbo P, Joffe K, Chue P, Metelitsa A, Wright E) 144

citalopram overdose

Citalopram overdose, serotonin toxicity, or neuroleptic malignant syndrome? [letter] (Isbister GK, Dawson A, Whyte IM) 657

Reply: citalopram overdose, serotonin toxicity, or neuroleptic malignant syndrome? (Aydin N, Anaç A, Çayköylü A, Akçay F) [letter] 658

Clerambault's syndrome

The misidentification of Clerambault's and Kandinsky-Clerambault's syndromes (Lerner V, Kaptzan A, Witzum E) 441

clinical guidelines

Clinical guidelines for the treatment of depressive disorders [supplement] (The Canadian Psychiatric Association, Canadian Network for Mood and Anxiety Treatments) 1S-92S

Re: clinical guidelines for the treatment of depressive disorders [letter] (Ney P) 987

clinical listening

Using language in psychiatry (Fine J) 916

clinical medicine

Recent advances in evidence-based psychiatry (Geddes J, Carney S) 403

clinical outcome

Consumer satisfaction with an adolescent inpatient psychiatric unit (Marriage K, Petrie P, Worling D) 969

clinical trials

Clinical trials in psychiatry: do results apply to practice? (Seeman MV) 352

clozapine

Suspected neuroleptic catatonia induced by clozapine [letter] (Biancosino B, Zanchi P, Agostini M, Grassi L) 458

Clozapine impact on clinical outcomes and aggression in severely ill adolescents with childhood-onset schizophrenia (Chalasan L, Kant R, KN Roy Chengappa KNR) 965

cognitive errors

Epidemiology of problem gambling in Prince Edward Island: a Canadian microcosm? (Doiron JP, Nicki RM) 413

combination drug therapy

Olanzapine augmentation of serotonin uptake inhibitors in obsessive-compulsive disorder: an open study (Francobandiera G) 356

committal criteria

Clinically significant differences among Canadian mental health acts (Gray JE, O'Reilly RL) 315

community treatment orders

Clinically significant differences among Canadian mental health acts (Gray JE, O'Reilly RL) 315

community psychiatry

Re: training residents for community psychiatric practice the resident perspective [letter] (Conlon P) 561

comorbidité

Lignes directrices cliniques du traitement des troubles dépressifs (Association des psychiatres du Canada, Canadian Network for Mood and Anxiety Treatments) 1S-92S

comorbidity

Clinical guidelines for the treatment of depressive disorders [supplement] (The Canadian Psychiatric Association, Canadian Network for Mood and Anxiety Treatments) 1S-92S

Comorbidity of phobic disorders with alcoholism in a Canadian community sample (Sareen J, Chartier M, Kjemistad KD, Stein MB) 733

compulsions

Obsessive compulsive disorder and psychosis (Ganesan V, Kumar TCR, Khanna S) 750

compulsive sexual behaviour

The neurobiology, neuropharmacology, and pharmacological treatment of the paraphilias and compulsive sexual behaviour (Bradford JMW) 26

Re: the neurobiology, neuropharmacology, and pharmacologic treatment of paraphilias and compulsive sexual behaviour [letter] (Haslam D, Adams S, Oluboka O) 559

conduct disorder

Conduct disorder: a challenge to child psychiatry [editorial] (Shamsie J) 593

Effective interventions for children and adolescents with conduct disorder (Frick PJ) 597

Conduct disorder: a biopsychosocial review (Bassarath L) 609

School dropout and conduct disorder in Brazilian elementary school students (Tramontina S, Martins S, Michalowski MB, Ketzer CR, Eizirik M, Biederman J, Rohde LA) 941

consumer satisfaction

Consumer satisfaction with an adolescent inpatient psychiatric unit (Marriage K, Petrie P, Worling D) 969

conventional antipsychotics

Antipsychotic metabolic effects: weight gain, diabetes mellitus, and lipid abnormalities (McIntyre RS, McCann SM, Kennedy SH) 273

costs

Economic impacts of supported employment for persons with severe mental illness (Latimer EA) 496

cost-effectiveness

Economic impacts of supported employment for persons with severe mental illness (Latimer EA) 496

crime

A social problem index for Canada (Thompson AH, Howard AW, Jin Y) 45

criminal harassment

Criminal harassment by patients with mental disorders (Adams SJ, Pitre NL, Smith A) 173

criminality

The neuropsychopharmacology of criminality and aggression (Lee R) 35

critical incidents

Individual predictors of posttraumatic distress: a structural equation model (Regehr C, Hemsworth D, Hill J) 156

Crohn's disease

Supportive-expressive group psychotherapy for inflammatory bowel disease (Maunder RG, Esplen MJ) 622

cross-sectional studies

"Diet pills" and major depression in the Canadian population (Patten SB) 438

crowding

Crowding and violence on psychiatric wards: explanatory models (Kumar S, Ng B) 433

cultural issues

Clinical guidelines for the treatment of depressive disorders [supplement] (The Canadian Psychiatric Association, Canadian Network for Mood and Anxiety Treatments) 1S-92S

D

databases

Using databases to prevent inpatient morbidity [letter] (Bristow K, Patten S) 455

delinquency

Conduct disorder: a biopsychosocial review (Bassarath L) 609

delirium

Delirium in psychiatric inpatients: a case-control study (Patten SB, Williams JVA, Petcu R, Oldfield R) 162

delusion

Metamorphosis of delusion of pregnancy [letter] (Battacharyya S, Chaturvedi SK) 561

delusional disorder

Clinical characteristics of delusional disorder [letter] (Hamuro A, Sugai Y, Isono H, Torii S) 563

dementia screening

Mild dementia or cognitive impairment: the modified mini-mental state examination (3ms) as a screen for dementia (Bland RC, Newman SC) 506

dependence

Gabapentin use in benzodiazepine dependence and detoxification [letter] (Crockford D, White WD, Campbell B) 287

depression

Clinical guidelines for the treatment of depressive disorders [supplement] (The Canadian Psychiatric Association, Canadian Network for Mood and Anxiety Treatments) 1S-92S

Adverse reactions to St John's wort (Parker V, Wong AHC, Boon HS, Seeman MV) 77

Lithium revisited (McIntyre RS, Mancini DA, Parikh S, Kennedy SH) 322

Moving from the clinic to the community: the alone mothers together program [letter] (Lipman EL, Secord M, Boyle MH) 657

Transcranial magnetic stimulation in the treatment of mood disorder: a review and comparison with electroconvulsive therapy (Hasey G) 720

Gabapentin use in geriatric patients with depression and bipolar illness [letter] (Robillard M, Conn D) 764

Left medial temporal cytosolic choline in early-onset depression (Kusumakar V, MacMaster FP, Gates L, Sparkes SJ, Khan SC) 959

Re: clinical guidelines for the treatment of depressive disorders [letter] (Ney P) 986

dépression

Lignes directrices cliniques du traitement des troubles dépressifs (Association des psychiatres du Canada, Canadian Network for Mood and Anxiety Treatments) 1S-92S

dépression chronique

Lignes directrices cliniques du traitement des troubles dépressifs (Association des psychiatres du Canada, Canadian Network for Mood and Anxiety Treatments) 1S-92S

depressive disorders

Clinical guidelines for the treatment of depressive disorders [supplement] (The Canadian Psychiatric Association, Canadian Network for Mood and Anxiety Treatments) 1S-92S

"Diet pills" and major depression in the Canadian population (Patten SB) 438

depressive disorder—chemically induced

"Diet pills" and major depression in the Canadian population (Patten SB) 438

development

Why are children in the same family so different? Nonshared environment a decade later (Plomin R, Asbury K, Dunn J) 225

developmental disabilities

Atypical antipsychotic use in treating adolescents and young adults with developmental disabilities (Friedlander RB, Lazar S, Klancnik J) 741

developmental disability

Developmental disability training in Canadian psychiatry residency programs (Lunskey Y, Bradley E) 138

Re: developmental disability training in Canadian psychiatry residency programs [letter] (Natarajan D) 863

developmental neurobiology

Developmental neurobiology: implications for pediatric psychopharmacology (Carrey N) 810

diabetes mellitus

Antipsychotic metabolic effects: weight gain, diabetes mellitus, and lipid abnormalities (McIntyre RS, McCann SM, Kennedy SH) 273

diagnosis

Using language in psychiatry (Fine J) 916

discourse

Discourse characteristics of subjects with schizophrenia and prominent negative symptoms [letter] (Noel-Jorand MC, Giudicelli S, Dassa D) 761

dissemination

Alcoholism: beliefs and attitudes among Canadian alcoholism treatment practitioners (Meza EE, Cunningham JA, el-Guebaly N, Couper L) 167

dissociative amnesia

Canadian and American psychiatrists' attitudes towards dissociative disorders diagnoses (Lalonde JK, Hudson JI, Gigante RA, Pope Jr HG) 407

dissociative disorders

Canadian and American psychiatrists' attitudes towards dissociative disorders diagnoses (Lalonde JK, Hudson JI, Gigante RA, Pope Jr HG) 407

dissociative identity disorder

Canadian and American psychiatrists' attitudes towards dissociative disorders diagnoses (Lalonde JK, Hudson JI, Gigante RA, Pope Jr HG) 407

dissociative symptoms

Attachment disorganization and dissociative symptoms in clinically treated adolescents (West M, Adam K, Spreng S, Rose S) 627

divalproex sodium

The effect of divalproex sodium on viral load: a retrospective review of HIV-positive patients with manic syndromes (Maggi JD Halman MH) 359

divorce

A social problem index for Canada (Thompson AH, Howard AW, Jin Y) 45

dopamine

Risperidone treatment of outpatients with schizophrenia: no evidence of sex differences in treatment response (Labelle A, Light M, Dunbar F) 534

droperidol

Evaluation of droperidol in the acutely agitated child or adolescent [letter] (Hameer O, Collin K, Ensom MHH, Lomax S) 864

drug advertising

Misleading drug advertising [letter] (Hoaken PCS) 660

drug interactions

Clinical guidelines for the treatment of depressive disorders [supplement] (The Canadian Psychiatric Association, Canadian Network for Mood and Anxiety Treatments) 1S-92S

Who develops severe or fatal adverse drug reactions to selective serotonin reuptake inhibitors (SSRIs)? (Dalfen AK, Devarajan S, Stewart DE) 258

DSM classification

Canadian and American psychiatrists' attitudes towards dissociative disorders diagnoses (Lalonde JK, Hudson JI, Gigante RA, Pope Jr HG) 407

dyskinesias

Atypical antipsychotic use in treating adolescents and young adults with developmental disabilities (Friedlander RB, Lazar S, Klancnik J) 741

dysthymic disorder

Clinical guidelines for the treatment of depressive disorders [supplement] (The Canadian Psychiatric Association, Canadian Network for Mood and Anxiety Treatments) 1S-92S

E**early intervention**

Treating psychosis: is there more to early intervention than intervening early? (Malla AM, Norman RMG) 645

early psychosis

The pharmacologic treatment of the early phase of first-episode psychosis in youths (Walter G, Wiltshire C, Anderson J, Storm V) 803

economics

Economic impacts of supported employment for persons with severe mental illness (Latimer EA) 496

edema

Risperidone-induced edema [letter] (Ravasia S) 453

education program

Educating the public about mental illness and homelessness: a cautionary note (Tolomiczenko GS, Goering PN, Durbin JF) 253

efficacité

Électroconvulsivothérapie chez l'adolescent : considérations cliniques à propos d'une série d'observations (Étain B, Le Heuzey M-F, Mouren-Simeoni M-C) 976

efficacy

Lithium revisited (McIntyre RS, Mancini DA, Parikh S, Kennedy SH) 322

elderly

Clinical guidelines for the treatment of depressive disorders [supplement] (The Canadian Psychiatric Association, Canadian Network for Mood and Anxiety Treatments) 1S-92S

The use of electroconvulsive therapy in special patient populations (Rabheru K) 710

Psychosocial risk factors in poststroke depression: a systematic review (Ouimet MA, Primeau F, Cole MG) 819

electroconvulsive therapy

Clinical guidelines for the treatment of depressive disorders [supplement] (The Canadian Psychiatric Association, Canadian Network for Mood and Anxiety Treatments) 1S-92S

Electroconvulsive therapy: the controversy and the evidence [editorial] (Persad E) 702

Electroconvulsive therapy's effect on suicide risk in patients with mood disorders (Sharma V) 704

The use of electroconvulsive therapy in special patient populations (Rabheru K) 710

Transcranial magnetic stimulation in the treatment of mood disorder: a review and comparison with electroconvulsive therapy (Hasey G) 720

Electroconvulsive therapy in cases of treatment-resistant psychosis [letter] (Parker V, Remington G) 762

électroconvulsivothérapie

Électroconvulsivothérapie chez l'adolescent : considérations cliniques à propos d'une série d'observations (Étain B, Le Heuzey M-F, Mouren-Simeoni M-C) 976

emotion

Factorial structure of the sensation-seeking scale-form V: confirmatory factorial analyses in nonclinical and clinical samples (Loas G, Verrier A, Flament MF, Perez-Diaz F, Corcos M, Halfon O, Lang F, Bizouard P, Venisse J-L, Gueffi JD, Jeammot P) 850

enseignement médical

« What's up, doc? » Le contexte, les limites et les enjeux de la médecine fondée sur des données probantes pour les cliniciens (evidence-based medicine) (Lesage AD, Stip E, Grunberg F) 396

environment

Behavioural genetic perspectives on personality function (Jang KL, Vernon PA, Livesley WJ) 234

environmental stress

Crowding and violence on psychiatric wards: explanatory models (Kumar S, Ng B) 433

épidémiologie génétique

Introduction à la psychiatrie génétique : progrès vers la découverte des gènes de susceptibilité aux troubles psychiatriques (Roy M-A, Mérette C, Maziade M) 52

epidemiology

Is schizophrenia on the decline in Canada? (Woogh C) 61

Delirium in psychiatric inpatients: a case-control study (Patten SB, Williams JVA, Petcu R, Oldfield R) 162

"Diet pills" and major depression in the Canadian population (Patten SB) 438

Comorbidity of phobic disorders with alcoholism in a Canadian community sample (Sareen J, Chartier M, Kjernisted KD, Stein MB) 733

Studying the epidemiology of attention-deficit hyperactivity disorder: screening method and pilot results (Rowland AS, Umbach DM, Catoe KE, Stallone L, Long S, Rabiner D, Nafel AJ, Panke D, Faulk R, Sandler DP) 931

eponyms

The misidentification of Clerambault's and Kandinsky-Clerambault's syndromes (Lerner V, Kapsan A, Witztum E) 441

erotomania

The misidentification of Clerambault's and Kandinsky-Clerambault's syndromes (Lerner V, Kapsan A, Witztum E) 441

étologie

Introduction à la psychiatrie génétique : progrès vers la découverte des gènes de susceptibilité aux troubles psychiatriques (Roy M-A, Mérette C, Maziade M) 52

evidence-based medicine

Recent advances in evidence-based psychiatry (Geddes J, Carney S) 403

evidence-based psychiatry

Evidence-based psychiatry: the pros and cons [editorial] (Dongier M) 394

externalizing disorders

Anxiety disorders in children and adolescents with bipolar disorder: a neglected comorbidity (Masi A, Toni C, Perugi G, Mucci M, Millepiedi S, Akiskal HS) 797

extrapyramidal symptoms

Risperidone Treatment of Outpatients With Schizophrenia: No Evidence of Sex Differences in Treatment Response (Labelle A, Light M, Dunbar F) 534

F**face-to-face contact**

Does the cellular phone help to communicate when face-to-face contacts are difficult? [letter] (Honkalampi K, Tanskanen A, Hintikka J, Haatainen K, Viinamäki H) 373

factorial analysis

Factorial structure of the Sensation-Seeking Scale-Form V: confirmatory factorial analyses in nonclinical and clinical samples (Loas G, Verrier A, Flament MF, Perez-Diaz F, Corcos M, Halfon O, Lang F, Bizouard P, Venisse J-L, Gueffi JD, Jeammot P) 850

familial

A family study of juvenile obsessive-compulsive disorder (Reddy PS, Reddy YCJ, Srinath S, Khanna S, Sheshadri SP, Girmaji SR) 346

families

Why are children in the same family so different? Nonshared environment a decade later (Plomin R, Asbury K, Dunn J) 225

fee-for-service

Using financial incentives to promote shared mental health care (Dewa CS, Hoch JS, Goering P) 488

fenfluramine

The neuropsychopharmacology of criminality and aggression (Lee R) 35

fibromyalgia

Tryptophan for treatment of rapid-cycling bipolar disorder comorbid with fibromyalgia [letter] (Sharma V, Barrett C) 452

financial incentives

using financial incentives to promote shared mental health care (Dewa CS, Hoch JS, Goering P) 488

first episode

Social functioning in first- and multipisode schizophrenia (Grant C, Addington J, Addington D, Konner C) 746

first-onset psychosis

The pharmacologic treatment of the early phase of first-episode psychosis in youths (Walter G, Wiltshire C, Anderson J, Storm V) 803

first-degree relatives

Polydipsia, psychosis, and familial psychopathology (Ahmed AG, Heigh LM, Ramachandran KV) 522

fitness to stand trial

Assessing fitness to stand trial: the utility of the fitness interview test (Revised Edition) (Zapf PA, Roesch R, Viljoen JL) 426

Fitness Interview Test

Assessing fitness to stand trial: the utility of the Fitness Interview Test (Revised Edition) (Zapf PA, Roesch R, Viljoen JL) 426

fluoxetine

Accelerated weight loss after treating refractory depression with fluoxetine plus topiramate: possible mechanisms of action? [letter] (Dursun SM) 287

fluvoxamine

Case of resistant trichotillomania treated with risperidone-augmented fluvoxamine [letter] (Gabriel A A) 285

fonctionnement social

Validation of the version française du health of the nation outcome scales (HoNOS-F) (Lauzon S, Corbière M, Bonin J-P, Bonsack C, Lesage AD, Ricard N) 841

forensic assessment

Assessing fitness to stand trial: the utility of the fitness interview test (revised edition) (Zapf PA, Roesch R, Viljoen JL) 426

frail elderly

The use of electroconvulsive therapy in special patient populations (Rabheru K) 710

frequency

Frequency of borderline personality disorder in a sample of French high school students (Chabrol H, Montovany A, Chouicha K, Callahan S, Mullet E) 847

functional linguistics

Using language in psychiatry (Fine J) 916

G**gabapentin**

Gabapentin use in benzodiazepine dependence and detoxification [letter] (Crockford D, White WD, Campbell B) 287

Gabapentin use in geriatric patients with depression and bipolar illness [letter] (Robillard M, Conn D) 764

galactorrhea

Galactorrhea induced by paroxetine [letter] (Morrison J, Remick RA, Leung M, Wrixon KJ, Bebb RA) 88

gender

Risperidone treatment of outpatients with schizophrenia: no evidence of sex differences in treatment response (Labelle A, Light M, Dunbar F) 534

general practitioner

Alternative medicine use by individuals with major depression (Wang J, Patten SB, Russell ML) 528

generalized anxiety disorder

Serum lipid concentrations in patients with comorbid generalized anxiety disorder and major depressive disorder (Sevincok L, Buyukozturk A, Dereboy F) 68

genes

Behavioural genetic perspectives on personality function (Jang KL, Vernon PA, Livesley WJ) 234

gènes de susceptibilité

Introduction à la psychiatrie génétique : progrès vers la découverte des gènes de susceptibilité aux troubles psychiatriques (Roy M-A, Mérette C, Maziade M) 52

genetic

A family study of juvenile obsessive-compulsive disorder (Reddy PS, Reddy YCI, Srinath S, Khanna S, Sheshadri SP, Girimaji SR) 346

genetic counselling

Genetic counselling for schizophrenia in the era of molecular genetics (Hodgkinson KA, Murphy J, O'Neill S, Brzustowicz L, Bassett AS) 123

genetics

Genetic insights into schizophrenia (Bassett AS, Chow EWC, Waterworth DM, Brzustowicz L) 131

Conduct disorder: a biopsychosocial review (Bassarath L) 609

Childhood-onset schizophrenia: research update (Kumra S, Shaw M, Merka P, Nakayama E, Augustin R) 923

génétique

Introduction à la psychiatrie génétique : progrès vers la découverte des gènes de susceptibilité aux troubles psychiatriques (Roy M-A, Mérette C, Maziade M) 52

geriatric

Gabapentin use in geriatric patients with depression and bipolar illness [letter] (Robillard M, Conn D) 764

geriatric psychiatry

What factors contribute to senior psychiatry residents' interest in geriatric psychiatry? [letter] (Reichenfeld HF) 374

Geriatric Mental State Examination

Mild dementia or cognitive impairment: the modified mini-mental state examination (3MS) as a screen for dementia (Bland RC, Newman SC) 506

global assessment of functioning

Global assessment of functioning following assertive community treatment in Edmonton, Alberta: a longitudinal study (Tibbo P, Joffe K, Chue P, Metelitsa A, Wright E) 144

Re: using global assessment of functioning to evaluate an assertive community treatment program [letter] (Malla A) 986

Using global assessment of functioning to evaluate an assertive community treatment program: reply [letter] (Chue PS) 986

gonadal steroids

Antipsychotic drugs and obesity: is prolactin involved? (Baptista T, Lacruz A, Meza T, Contreras Q, Delgado C, Mejias MA, Hernández L) 829

Griffin, John Douglas Morecroft

In memoriam: John Douglas Morecroft Griffin (Greenland C, Kajander R) 595

group psychotherapy

Supportive-expressive group psychotherapy for inflammatory bowel disease (Mauder RG, Esplen MJ) 622

guide de pratique clinique

Lignes directrices cliniques du traitement des troubles dépressifs (Association des psychiatres du Canada, Canadian Network for Mood and Anxiety Treatments) 1S-92S

guidelines

Clinical guidelines for the treatment of depressive disorders [supplement] (The Canadian Psychiatric Association, Canadian Network for Mood and Anxiety Treatments) 1S-92S

Recent advances in evidence-based psychiatry (Geddes J, Carney S) 403

H**health burden**

Clinical guidelines for the treatment of depressive disorders [supplement] (The Canadian Psychiatric Association, Canadian Network for Mood and Anxiety Treatments) 1S-92S

New century: overcoming stigma, respecting differences [presidential address] Myers M 907

health economics

The contributions of health economics to mental health policy [editorial] (Gnam WH) 486

health status

Posttraumatic stress disorder, trauma exposure, and the current health of Canadian bus drivers (Vedantham K, Brunet A, Boyer R, Weiss DS, Metzler TJ, Marmar CR) 149

herbal remedies

Adverse reactions to St John's wort (Parker V, Wong AHC, Boon HS, Seeman MV) 77

herbs

Adverse reactions to St John's wort (Parker V, Wong AHC, Boon HS, Seeman MV) 77

hétérogénéité

Introduction à la psychiatrie génétique : progrès vers la découverte des gènes de susceptibilité aux troubles psychiatriques (Roy M-A, Mérette C, Maziade M) 52

5-HIAA

The neuropsychopharmacology of criminality and aggression (Lee R) 35

high-density lipoprotein cholesterol

Serum lipid concentrations in patients with comorbid generalized anxiety disorder and major depressive disorder (Sevincok L, Buyukozturk A, Dereboy F) 68

HIV

The effect of divalproex sodium on viral load: a retrospective review of HIV-positive patients with manic syndromes (Maggi JD, Halman MH) 359

HIV-1 viral load

The effect of divalproex sodium on viral load: a retrospective review of HIV-positive patients with manic syndromes (Maggi JD, Halman MH) 359

home visits

Home visits from an outpatient psychiatric clinic [letter] (Moldavsky D, Szor H, Melamed Y, Levi D, Elizur A) 562

homelessness

Educating the public about mental illness and homelessness: a cautionary note (Tolomiczenko GS, Goering PN, Durbin JF) 253

hyperglycemia

Olanzapine-related hyperglycemia in a nondiabetic woman [letter] (Kropp S, Emrich HM, Bleich S, Degner D) 457

hypersexuality

The neurobiology, neuropharmacology, and pharmacological treatment of the paraphilias and compulsive sexual behaviour (Bradford JMW) 26

hypomania

Is the minimum duration of hypomania in bipolar II disorder 4 days? [letter] (Benazzi F) 86

Quetapine-associated hypomania in a woman with schizoaffective disorder [letter] (Benazzi F) 182

Venlafaxine-induced hypomanic switch in bipolar depression [letter] (Gupta N) 760

hypoxia

Pre-, peri-, and postnatal trauma in subjects with attention-deficit hyperactivity disorder (Zappitelli M, Pinto T, Grizenko N) 542

I

impulsiveness

The neuropsychopharmacology of criminality and aggression (Lee R) 35

index

A social problem index for Canada (Thompson AH, Howard AW, Jin Y) 45

individual difference

Clinical trials in psychiatry: do results apply to practice? (Seeman MV) 352

individual placement and support

Economic impacts of supported employment for persons with severe mental illness (Latimer EA) 496

inflammatory bowel disease

Supportive-expressive group psychotherapy for inflammatory bowel disease (Mauder RG, Esplen MJ) 622

information systems

Recent advances in evidence-based psychiatry (Geddes J, Carney S) 403

inositol

Mania associated with an energy drink: the possible role of caffeine, taurine, and inositol [letter] (Machado-Vieira R, Viale CI, Kapczinski F) 454

inpatient morbidity

Using databases to prevent inpatient morbidity [letter] (Bristow K, Patten S) 455

insulin sensitivity

Antipsychotic drugs and obesity: is prolactin involved? (Baptista T, Lacruz A, Meza T, Contreras Q, Delgado C, Mejias MA, Hernández L) 829

intentional overdose

Who develops severe or fatal adverse drug reactions to selective serotonin reuptake inhibitors (SSRIs)? (Dalfen AK, Devarajan S, Stewart DE) 258

interaction

Using language in psychiatry (Fine J) 916

interactions médicamenteuses

Lignes directrices cliniques du traitement des troubles dépressifs (Association des psychiatres du Canada, Canadian Network for Mood and Anxiety Treatments) 1S-92S

Internet

"Internet delusion" in a patient with a schizoaffective disorder [letter] (Kobayashi T, Okada Y, Nisijima K, Kato S) 89

« What's up, doc? » Le contexte, les limites et les enjeux de la médecine fondée sur des données probantes pour les cliniciens (evidence-based medicine) (Lesage AD, Stip E, Grunberg F) 396

intravenous

The Use of Intravenous Valproate in Psychiatry [letter] (Norton J) 371

J

job satisfaction

Predictors of success and satisfaction in the practice of psychiatry: a preliminary follow-up study (Garfinkel PE, Bagby RM, Schuller DR, Williams CC, Dickens SE, Dorian B) 835

K

Kandinsky-Clerambault's syndrome

The misidentification of Clerambault's and Kandinsky-Clerambault's syndromes (Lerner V, Kaptan A, Witztum E) 441

L

labour complications

Pre-, peri-, and postnatal trauma in subjects with attention-deficit hyperactivity disorder (Zappitelli M, Pinto T, Grizenko N) 542

lamotrigine

Lamotrigine: a review of clinical studies in bipolar disorders (Zerjav-Lacombe S, Tabarsi E) 328

language

Discourse characteristics of subjects with schizophrenia and prominent negative symptoms [letter] (Noel-Jordan MC, Giudicelli S, Dassa D) 761

Using language in psychiatry (Fine J) 916

laryngeal dystonia

Laryngeal dystonia in psychiatry [letter] (Norton J) 453

LHRH agonists

The neurobiology, neuropharmacology, and pharmacological treatment of the paraphilias and compulsive sexual behaviour (Bradford JMW) 26

liaison génétique

Introduction à la psychiatrie génétique : progrès vers la découverte des gènes de susceptibilité aux troubles psychiatriques (Roy M-A, Mérette C, Maziade M) 52

lifestyle

Predictors of success and satisfaction in the practice of psychiatry: a preliminary follow-up study (Garfinkel PE, Bagby RM, Schuller DR, Williams CC, Dickens SE, Dorian B) 835

light therapy

Clinical guidelines for the treatment of depressive disorders [supplement] (The Canadian Psychiatric Association, Canadian Network for Mood and Anxiety Treatments) 1S-92S

limbic system

Neuroimaging studies of antisocial behaviour (Bassarath L) 728

linkage

Genetic insights into schizophrenia (Bassett AS, Chow EWC, Waterworth DM, Brzustowicz L) 131

lithium

Lithium revisited (McIntyre RS, Mancini DA, Parikh S, Kennedy SH) 322

low-density lipoprotein cholesterol

Serum lipid concentrations in patients with comorbid generalized anxiety disorder and major depressive disorder (Sevincok L, Buyukozturk A, Dereboy F) 68

lycanthropy

Lycanthropy: 2 case reports [letter] (Gödecke-Koch T, Garlipp P, Haltenhof H, Dietrich DE) 659

M

magnetic resonance imaging

Neuroimaging studies of antisocial behaviour (Bassarath L) 728

magnetic resonance spectroscopy

Left medial temporal cytosolic choline in early-onset depression (Kusumakar V, MacMaster FP, Gates L, Sparkes SJ, Khan SC) 959

maintenance therapy

Clinical guidelines for the treatment of depressive disorders [supplement] (The Canadian Psychiatric Association, Canadian Network for Mood and Anxiety Treatments) 1S-92S

major depression

A prospective study of sex-specific effects of major depression on alcohol consumption (Wang J, Patten SB) 422

Alternative medicine use by individuals with major depression (Wang J, Patten SB, Russell ML) 528

Alcohol consumption and major depression: findings from a follow-up study (Wang J, Patten SB) 632

major depressive disorder

Clinical guidelines for the treatment of depressive disorders [supplement] (The Canadian Psychiatric Association, Canadian Network for Mood and Anxiety Treatments) 1S-92S

Serum lipid concentrations in patients with comorbid generalized anxiety disorder and major depressive disorder (Sevincok L, Buyukozturk A, Dereboy F) 68

management

Clinical guidelines for the treatment of depressive disorders [supplement] (The Canadian Psychiatric Association, Canadian Network for Mood and Anxiety Treatments) 1S-92S

mania

The effect of divalproex sodium on viral load: a retrospective review of HIV-positive patients with manic syndromes (Maggi JD, Halman MH) 359

Mania associated with an energy drink: the possible role of caffeine, taurine, and inositol [letter] (Machado-Vieira R, Viale CI, Kapczinski F) 454

Gabapentin as a prophylaxis against steroid-induced mania [letter] (Ginsberg DL, Sussman N) 455

medical informatics

Recent advances in evidence-based psychiatry (Geddes J, Carney S) 403

medically ill

The use of electroconvulsive therapy in special patient populations (Rabheru K) 710

medication

Clinical guidelines for the treatment of depressive disorders [supplement] (The Canadian Psychiatric Association, Canadian Network for Mood and Anxiety Treatments) 1S-92S

mental disorder

Criminal harassment by patients with mental disorders (Adams SJ, Pitre NL, Smith A) 173

mental health acts

Clinically significant differences among Canadian mental health acts (Gray JE, O'Reilly RL) 315

mental health promotion

Community attitudes toward people with schizophrenia (Stuart H, Arboleda-Florez J) 245

mental automatism

The misidentification of Clerambault's and Kandinsky-Clerambault's syndromes (Lerner V, Kapsan A, Witzum E) 441

mental health policy

The contributions of health economics to mental health policy [editorial] (Gnam WH) 486

mental illness

Educating the public about mental illness and homelessness: a cautionary note (Tolomiczenko GS, Goering PN, Durbin JF) 253

Economic impacts of supported employment for Persons With Severe Mental Illness (Latimer EA) 496

mental retardation

Developmental disability training in Canadian psychiatry residency programs (Lunskey Y, Bradley E) 138

Atypical antipsychotic use in treating adolescents and young adults with developmental disabilities (Friedlander RB, Lazar S, Klancnik J) 741

méta-analyses

« What's up, doc? » Le contexte, les limites et les enjeux de la médecine fondée sur des données probantes pour les cliniciens (evidence-based medicine) (Lesage AD, Stip E, Grunberg F) 396

methods

Studying the epidemiology of attention-deficit hyperactivity disorder: screening method and pilot results (Rowland AS, Umbach DM, Catoe KE, Stallone L, Long S, Rabiner D, Naftel AJ, Panke D, Faulk R, Sandler DP) 931

méthodes diagnostiques

Introduction à la psychiatrie génétique : progrès vers la découverte des gènes de susceptibilité aux troubles psychiatriques (Roy M-A, Mérette C, Maziade M) 52

methylphenidate

Obsessive-compulsive symptoms secondary to methylphenidate treatment [letter] (Kotsopoulos S, Spivak M) 89

metoclopramide

Ondansetron rather than metoclopramide for bupropion-induced nausea [letter] (Lara DR, Busnello ED, Souza DO) 371

Modified Mini-Mental State Examination

Mild dementia or cognitive impairment: the modified mini-mental state examination (3MS) as a screen for dementia (Bland RC, Newman SC) 506

molecular genetics

Behavioural genetic perspectives on personality function (Jang KL, Vernon PA, Livesley WJ) 234

mood stabilizers

Treatment of mixed mania with risperidone and mood stabilizers [letter] (Benabarre A, Vieta E, Colom F, Martinez A, Reinares M, Corbella B) 866

mood disorders

Electroconvulsive therapy's effect on suicide risk in patients with mood disorders (Sharma V) 704

mothers

Moving from the clinic to the community: the alone mothers together program [letter] (Lipman EL, Secord M, Boyle MH) 657

motivation

Le concept français d'athymhormie de 1922 à nos jours (Luauté J-P, Saladini O) 639

multiple regression

Epidemiology of problem gambling in Prince Edward Island: a Canadian microcosm? (Doiron JP, Nicki RM) 413

N**nausea**

Ondansetron rather than metoclopramide for bupropion-induced nausea [letter] (Lara DR, Busnello ED, Souza DO) 371

negative symptoms

Discourse characteristics of subjects with schizophrenia and prominent negative symptoms [letter] (Noel-Jorand MC, Giudicelli S, Dassa D) 761

neuroimaging

Childhood-onset schizophrenia: research update (Kumra S, Shaw M, Merka P, Nakayama E, Augustin R) 923

neuroleptic

Sudden death following neuroleptic administration due to hemoperitoneum resulting from physical restraint [letter] (Raju GVL, Ramesh Kumar TC, Khanna S) 372

neuroleptic catatonia

Suspected neuroleptic catatonia induced by clozapine [letter] (Biancosino B, Zanchi P, Agostini M, Grassi L) 458

neuroleptic malignant syndrome

Neuroleptic malignant syndrome associated with quetiapine [letter] (Karagianis J, Phillips L, Hogan K, LeDrew K) 370

Neuroleptic malignant syndrome associated with quetiapine: a response [letter] (Al-Waneen R) 370

Citalopram overdose, serotonin toxicity, or neuroleptic malignant syndrome? [letter] (Isbister GK, Dawson A, Whyte IM) 657

Reply: citalopram overdose, serotonin toxicity, or neuroleptic malignant syndrome? (Aydin N, Anaç A, Çayköylü A, Akçay F) [letter] 658

Atypical antipsychotics and neuroleptic malignant syndrome [letter] (Vela-moor VR) 865

Reply: atypical antipsychotics and neuroleptic malignant syndrome [letter] (Biancosino B, Grassi L) 866

neuroprotective

Developmental neurobiology: implications for pediatric psychopharmacology (Carrey N) 810

neuropsychiatry

Le concept français d'athymhormie de 1922 à nos jours (Luauté J-P, Saladini O) 639

neurotoxic

Developmental neurobiology: implications for pediatric psychopharmacology (Carrey N) 810

nonresponders

Lamotrigine: a review of clinical studies in bipolar disorders (Zerjav-Lacombe S, Tabarsi E) 328

nonshared environment

Why are children in the same family so different? Nonshared environment a decade later (Plomin R, Asbury K, Dunn J) 225

O**obesity**

Antipsychotic metabolic effects: weight gain, diabetes mellitus, and lipid abnormalities (McIntyre RS, McCann SM, Kennedy SH) 273

Body mass index in persons with schizophrenia (Coodin S) 549

Antipsychotic drugs and obesity: is prolactin involved? (Baptista T, Lacruz A, Meza T, Contreras Q, Delgado C, Mejias MA, Hernández L) 829

obesity comorbidity

Antipsychotic metabolic effects: weight gain, diabetes mellitus, and lipid abnormalities (McIntyre RS, McCann SM, Kennedy SH) 273

obsessions

Obsessive compulsive disorder and psychosis (Ganesan V, Kumar TCR, Khanna S) 750

obsessive-compulsive disorder

Obsessive-compulsive symptoms secondary to methylphenidate treatment [letter] (Kotsopoulos S, Spivak M) 89

A family study of juvenile obsessive-compulsive disorder (Reddy PS, Reddy YCJ, Srinath S, Khanna S, Sheshadri SP, Girimaji SR) 346

Olanzapine augmentation of serotonin uptake inhibitors in obsessive-compulsive disorder: an open study (Francobandiera G) 356

olanzapine

Supersensitivity psychosis in patients with schizophrenia after sudden olanzapine withdrawal [letter] (Llorca P-M, Vaiva G, Lancon C) 87

Treatment of posttraumatic stress disorder with olanzapine [letter] (Prior TI) 182

Re: Treatment of posttraumatic stress disorder with olanzapine [letter] (Labbate LA, Douglas S) 182

Olanzapine augmentation of serotonin uptake inhibitors in obsessive-compulsive disorder: an open study (Francobandiera G) 356

Olanzapine-related hyperglycemia in a nondiabetic woman [letter] (Kropp S, Emrich HM, Bleich S, Degner D) 457

olfaction

Regional cerebral glucose metabolism in never-medicated patients with schizophrenia (Clark C, Kopala L, Li DK, Hurwitz T) 340

ondansetron

Ondansetron rather than metoclopramide for bupropion-induced nausea [letter] (Lara DR, Busnello ED, Souza DO) 371

Ontario Health Survey

Comorbidity of phobic disorders with alcoholism in a Canadian community sample (Sareen J, Chartier M, Kjemistad KD, Stein MB) 733

oppositional defiant disorder

Correlation between anxiety and oppositionality in a children's mood and anxiety disorder clinic (Garland EJ, Garland OM) 953

organic mental disorder

Delirium in psychiatric inpatients: a case-control study (Patten SB, Williams JVA, Petcu R, Oldfield R) 162

outpatient clinic

Home visits from an outpatient psychiatric clinic [letter] (Moldavsky D, Szor H, Melamed Y, Levi D, Elizur A) 562

overdose

Fatal chloral hydrate overdoses: unnecessary tragedies [letter] (Frankland A, Robinson MJ) 763

P

panic disorder

Separation anxiety and actual separation experiences during childhood in patients with panic disorder (Bandelow B, Alvarez Tichauer GA, Späth C, Broocks A, Hajak G, MD5, Bleich S, Rüther E) 948

paraphilias

The neurobiology, neuropharmacology, and pharmacological treatment of the paraphilias and compulsive sexual behaviour (Bradford JMW) 26

Re: the neurobiology, neuropharmacology, and pharmacologic treatment of paraphilias and compulsive sexual behaviour [letter] (Haslam D, Adams S, Oluboka O) 559

parkinsonism

Bupropion and drug-induced parkinsonism [letter] (Jerome L) 560

paroxetine

Galactorrhea induced by paroxetine [letter] (Morrison J, Remick RA, Leung M, Wrixon KJ, Bebb RA) 88

pathological aggression

Neuropsychopharmacology of pathological aggression and sexuality [guest editorial] (Keegan DL) 24

pathological gambling

Epidemiology of problem gambling in Prince Edward Island: a Canadian microcosm? (Doiron JP, Nicki RM) 413

A profile of Canadian adults seeking treatment for gambling problems and comparisons with adults entering an alcohol treatment program (Wiebe J, Cox BJ) 418

pediatric psychopharmacology

Developmental neurobiology: implications for pediatric psychopharmacology (Carrey N) 810

pénétrance

Introduction à la psychiatrie génétique : progrès vers la découverte des gènes de susceptibilité aux troubles psychiatriques (Roy M-A, Mérette C, Maziade M) 52

perfectionism

The phenomenology of perfectionism: "yumpity" [letter] (Bilsbury C, Tang M, Bilsbury J) 863

perinatal

Pre-, peri-, and postnatal trauma in subjects with attention-deficit hyperactivity disorder (Zappitelli M, Pinto T, Grizenko N) 542

peritraumatic dissociation

Peritraumatic dissociation, acute stress, and early posttraumatic stress disorder in victims of general crime (Birmes P, Carreras D, Ducassé J-L, Charlet J-P, Warner BA, Lauque D, Laurent Schmitt L) 649

personality

Behavioural genetic perspectives on personality function (Jang KL, Vernon PA, Livesley WJ) 234

Predictors of success and satisfaction in the practice of psychiatry: a preliminary follow-up study (Garfinkel PE, Bagby RM, Schuller DR, Williams CC, Dickens SE, Dorian B) 835

personality disorder

Behavioural genetic perspectives on personality function (Jang KL, Vernon PA, Livesley WJ) 234

perte d'auto-activation psychique

Le concept français d'athymormie de 1922 à nos jours (Luauté J-P, Saladini O) 639

pharmacochallenge

The neuropsychopharmacology of criminality and aggression (Lee R) 35

pharmacologic hypomania

Anxiety disorders in children and adolescents with bipolar disorder: a neglected comorbidity (Masi A, Toni C, Perugi G, Mucci M, Millepiedi S, Akiskal HS) 797

pharmacologic treatment

The pharmacologic treatment of the early phase of first-episode psychosis in youths (Walter G, Wiltshire C, Anderson J, Storm V) 803

pharmacothérapie

Lignes directrices cliniques du traitement des troubles dépressifs (Association des psychiatres du Canada, Canadian Network for Mood and Anxiety Treatments) 1S-92S

pharmacotherapy

Clinical guidelines for the treatment of depressive disorders [supplement] (The Canadian Psychiatric Association, Canadian Network for Mood and Anxiety Treatments) 1S-92S

Alcoholism: beliefs and attitudes among Canadian alcoholism treatment practitioners (Meza EE, Cunningham JA, el-Guebaly N, Couper L) 167

phénotype

Introduction à la psychiatrie génétique : progrès vers la découverte des gènes de susceptibilité aux troubles psychiatriques (Roy M-A, Mérette C, Maziade M) 52

phobia

Comorbidity of phobic disorders with alcoholism in a Canadian community sample (Sareen J, Chartier M, Kjemistad KD, Stein MB) 733

photothérapie

Lignes directrices cliniques du traitement des troubles dépressifs (Association des psychiatres du Canada, Canadian Network for Mood and Anxiety Treatments) 1S-92S

physical abuse

Physical and sexual abuse issues among youths with substance use problems (Ballon BC, Courbasson CMA, Smith PD) 617

polydipsia

Polydipsia, Psychosis, and Familial Psychopathology (Ahmed AG, Heigh LM, Ramachandran KV) 522

polypharmacy

Antipsychotic polypharmacy: a survey of discharge prescriptions from a tertiary care psychiatric institution (Procyshyn RM, Kennedy NB, Tse G, Thompson B) 334

population-based rates

Attention-deficit hyperactivity disorder in Manitoba children: medical diagnosis and psychostimulant treatment rates (Brownell MD, Yogendran MS) 264

populations particulières

Lignes directrices cliniques du traitement des troubles dépressifs (Association des psychiatres du Canada, Canadian Network for Mood and Anxiety Treatments) 1S-92S

positron emission tomography

Neuroimaging studies of antisocial behaviour (Bassarath L) 728

postnatal

Pre-, peri-, and postnatal trauma in subjects with attention-deficit hyperactivity disorder (Zappitelli M, Pinto T, Grizenko N) 542

postpartum

The use of electroconvulsive therapy in special patient populations (Rabheru K) 710

postpartum depression

Clinical guidelines for the treatment of depressive disorders [supplement] (The Canadian Psychiatric Association, Canadian Network for Mood and Anxiety Treatments) 1S-92S

poststroke depression

Psychosocial risk factors in poststroke depression: a systematic review (Ouimet MA, Primeau F, Cole MG) 819

posttraumatic stress disorder

Posttraumatic stress disorder, trauma exposure, and the current health of Canadian bus drivers (Vedantham K, Brunet A, Boyer R, Weiss DS, Metzler TJ, Marmar CR) 149

Treatment of posttraumatic stress disorder with olanzapine [letter] (Prior TI) 182

Re: Treatment of Posttraumatic Stress Disorder With Olanzapine [letter] (Labbate LA, Douglas S) 182

Peritraumatic dissociation, acute stress, and early posttraumatic stress disorder in victims of general crime (Birmes P, Carreras D, Ducassé J-L, Charlet J-P, Warner BA, Lauque D, Laurent Schmitt L) 649

poverty

Moving from the clinic to the community: the alone mothers together program [letter] (Lipman EL, Secord M, Boyle MH) 657

prefrontal cortex

Neuroimaging studies of antisocial behaviour (Bassarath L) 728

pregnancy

Clinical guidelines for the treatment of depressive disorders [supplement] (The Canadian Psychiatric Association, Canadian Network for Mood and Anxiety Treatments) 1S-92S

Neurobiology of the use of selective serotonin reuptake inhibitors during pregnancy [letter] (Friedman EH) 371

Neurobiology of the use of selective serotonin reuptake inhibitors during pregnancy: response [letter] (Jerome L) 452

Metamorphosis of delusion of pregnancy [letter] (Battacharyya S, Chaturvedi SK) 561

The use of electroconvulsive therapy in special patient populations (Rabheru K) 710

premenstrual dysphoric disorder

Clinical guidelines for the treatment of depressive disorders [supplement] (The Canadian Psychiatric Association, Canadian Network for Mood and Anxiety Treatments) 1S-92S

prenatal

Pre-, peri-, and postnatal trauma in subjects with attention-deficit hyperactivity disorder (Zappitelli M, Pinto T, Grizenko N) 542

prevalence

Studying the epidemiology of attention-deficit hyperactivity disorder: screening method and pilot results (Rowland AS, Umbach DM, Catoe KE, Stallone L, Long S, Rabiner D, Naftel AJ, Panke D, Faulk R, Sandler DP) 931

prevalence rates

Is schizophrenia on the decline in Canada? (Woogh C) 61

prevention

Effective interventions for children and adolescents with conduct disorder (Frick PJ) 597

prison suicides

What was the relevance of previous suicidal behaviour in prison suicides? [letter] (Fruchwald S, Eher R, Frottier P) 763

problem gambling

Epidemiology of problem gambling in Prince Edward Island: a Canadian microcosm? (Doiron JP, Nicki RM) 413

A profile of Canadian adults seeking treatment for gambling problems and comparisons with adults entering an alcohol treatment program (Wiebe J, Cox BJ) 418

prodrome

The pharmacologic treatment of the early phase of first-episode psychosis in youths (Walter G, Wiltshire C, Anderson J, Storm V) 803

prolactin

Antipsychotic drugs and obesity: is prolactin involved? (Baptista T, Lacruz A, Meza T, Contreras Q, Delgado C, Mejias MA, Hernández L) 829

protective factors

Conduct disorder: a biopsychosocial review (Bassarath L) 609

psychiatric inpatients

Polydipsia, psychosis, and familial psychopathology (Ahmed AG, Heigh LM, Ramachandran KV) 522

psychiatric case register

Is schizophrenia on the decline in Canada? (Woogh C) 61

psychiatric disability

Economic impacts of supported employment for Persons With Severe Mental Illness (Latimer EA) 496

psychiatric genetics

Genetic counselling for schizophrenia in the era of molecular genetics (Hodgkinson KA, Murphy J, O'Neill S, Brzustowicz L, Bassett AS) 123

Genetic insights into schizophrenia (Bassett AS, Chow EWC, Waterworth DM, Brzustowicz L) 131

Psychiatric genetics in the 21st century [editorial] (Bassett AS) 121

psychiatrist

Predictors of success and satisfaction in the practice of psychiatry: a preliminary follow-up study (Garfinkel PE, Bagby RM, Schuller DR, Williams CC, Dickens SE, Dorian B) 835

psychological trauma

Posttraumatic stress disorder, trauma exposure, and the current health of Canadian bus drivers (Vedantham K, Brunet A, Boyer R, Weiss DS, Metzler TJ, Marmar CR) 149

psychopathology

Polydipsia, psychosis, and familial psychopathology (Ahmed AG, Heigh LM, Ramachandran KV) 522

psychose

Schizophrénie et psychothérapies cognitivo-comportementales (Abdel-Baki A, Nicole L) 511

psychoses

Introduction à la psychiatrie génétique : progrès vers la découverte des gènes de susceptibilité aux troubles psychiatriques (Roy M-A, Mérette C, Maziade M) 52

psychosis

Treating psychosis: is there more to early intervention than intervening early? (Malla AM, Norman RMG) 645

Obsessive-compulsive disorder and psychosis (Ganesan V, Kumar TCR, Khanna S) 750

psychosocial

Psychosocial risk factors in poststroke depression: a systematic review (Ouimet MA, Primeau F, Cole MG) 819

psychosomatics

Posttraumatic Stress disorder, trauma exposure, and the current health of Canadian bus drivers (Vedantham K, Brunet A, Boyer R, Weiss DS, Metzler TJ, Marmar CR) 149

psychostimulants

Attention-deficit hyperactivity disorder in Manitoba children: medical diagnosis and psychostimulant treatment rates (Brownell MD, Yogendran MS) 264

psychothérapie cognitive

Schizophrénie et psychothérapies cognitivo-comportementales (Abdel-Baki A, Nicole L) 511

psychothérapie

Schizophrénie et psychothérapies cognitivo-comportementales (Abdel-Baki A, Nicole L) 511

Lignes directrices cliniques du traitement des troubles dépressifs (Association des psychiatres du Canada, Canadian Network for Mood and Anxiety Treatments) 1S-92S

psychothérapie cognitivo-béaviorale

Schizophrénie et psychothérapies cognitivo-comportementales (Abdel-Baki A, Nicole L) 511

psychothérapie cognitivo-comportementale

Schizophrénie et psychothérapies cognitivo-comportementales (Abdel-Baki A, Nicole L) 511

psychotherapy

Clinical guidelines for the treatment of depressive disorders [supplement] (The Canadian Psychiatric Association, Canadian Network for Mood and Anxiety Treatments) 1S-92S

public attitudes

Community attitudes toward people with schizophrenia (Stuart H, Arboleda-Florez J) 245

Q**quality of life**

Supportive-expressive group psychotherapy for inflammatory bowel disease (Mauder RG, Esplen MJ) 622

quetiapine

Combination risperidone and quetiapine therapy in refractory schizophrenia [letter] (Chue P, Welch R, Snaterse M) 86

Quetiapine-associated hypomania in a woman with schizoaffective disorder [letter] (Benazzi F) 182

Quetiapine treatment in patients with Tourette syndrome [letter] (Párraga HC, Párraga MI) 184

Neuroleptic malignant syndrome associated with quetiapine [letter] (Karagianis J, Phillips L, Hogan K, LeDrew K) 370

Neuroleptic malignant syndrome associated with quetiapine: a response [letter] (Al-Waneen R) 370

R**recherche clinique**

« What's up, doc? » Le contexte, les limites et les enjeux de la médecine fondée sur des données probantes pour les cliniciens (evidence-based medicine) (Lesage AD, Stip E, Grunberg F) 396

refractory depression

Accelerated weight loss after treating refractory depression with fluoxetine plus topiramate: possible mechanisms of action? [letter] (Dursun SM) 287

regional variations

Attention-deficit hyperactivity disorder in Manitoba children: medical diagnosis and psychostimulant treatment rates (Brownell MD, Yogendran MS) 264

regression toward the mean

Regression toward the mean: its etiology, diagnosis, and treatment (Streiner DL) 72

relational capacity

Individual predictors of posttraumatic distress: a structural equation model (Regehr C, Hemsworth D, Hill J) 156

reliability

Regression toward the mean: its etiology, diagnosis, and treatment (Streiner DL) 72

renal toxicity

Lithium revisited (McIntyre RS, Mancini DA, Parikh S, Kennedy SH) 322

representativeness

Clinical trials in psychiatry: do results apply to practice? (Seeman MV) 352

répercussions sanitaires

Lignes directrices cliniques du traitement des troubles dépressifs (Association des psychiatres du Canada, Canadian Network for Mood and Anxiety Treatments) 1S-92S

residency training

Developmental disability training in Canadian psychiatry residency programs (Lunsky Y, Bradley E) 138

residents

What factors contribute to senior psychiatry residents' interest in geriatric psychiatry? [letter] (Reichenfeld HF) 374

Re: training residents for community psychiatric practice the resident perspective [letter] (Conlon P) 561

restraint

Clozapine impact on clinical outcomes and aggression in severely ill adolescents with childhood-onset schizophrenia (Chalasani L, Kant R, KN Roy Chengappa KNR) 965

reverse causation

A prospective study of sex-specific effects of major depression on alcohol consumption (Wang J, Patten SB) 422

review

Childhood-onset schizophrenia: research update (Kumra S, Shaw M, Merka P, Nakayama E, Augustin R) 923

risk factors

Posttraumatic Stress disorder, trauma exposure, and the current health of Canadian bus drivers (Vedantham K, Brunet A, Boyer R, Weiss DS, Metzler TJ, Marmar CR) 149

Delirium in psychiatric inpatients: a case-control study (Patten SB, Williams JVA, Petcu R, Oldfield R) 162

Conduct disorder: a biopsychosocial review (Bassarath L) 609

Peritraumatic dissociation, acute stress, and early posttraumatic stress disorder in victims of general crime (Birmes P, Carreras D, Ducassé J-L, Charlet J-P, Warner BA, Lauque D, Laurent Schmitt L) 649

Psychosocial risk factors in poststroke depression: a systematic review (Ouimet MA, Primeau F, Cole MG) 819

risperidone

Combination risperidone and quetiapine therapy in refractory schizophrenia [letter] (Chue P, Welch R, Snaterse M) 86

Case of resistant trichotillomania treated with risperidone-augmented fluvoxamine [letter] (Gabriel A) 285

Risperidone-induced edema [letter] (Ravasia S) 453

Risperidone Treatment of Outpatients With Schizophrenia: No Evidence of Sex Differences in Treatment Response (Labelle A, Light M, Dunbar F) 534

Open-Label Risperidone Treatment of 6 Children and Adolescents With Autism [letter] (Vercellino F, Zanotto E, Ravera G, Veneselli E) 559

Does risperidone reduce concomitant substance abuse in cases of schizophrenia? [letter] (Gupta N, Basu D) 862

Treatment of mixed mania with risperidone and mood stabilizers [letter] (Benabarre A, Vieta E, Colom F, Martinez A, Reinares M, Corbella B) 866

S**santé mentale**

Validation de la version française du health of the nation outcome scales (HoNOS-F) (Lauzon S, Corbière M, Bonin J-P, Bonsack C, Lesage AD, Ricard N) 841

schizoaffective

Clozapine impact on clinical outcomes and aggression in severely ill adolescents with childhood-onset schizophrenia (Chalasani L, Kant R, KN Roy Chengappa KNR) 965

schizoaffective disorder

"Internet delusion" in a patient with a schizoaffective disorder [letter] (Kobayashi T, Okada Y, Nisijima K, Kato S) 89

schizophrenia

Is schizophrenia on the decline in Canada? (Woogh C) 61

Supersensitivity psychosis in patients with schizophrenia after sudden olanzapine withdrawal [letter] (Llorca P-M, Vaiva G, Lancon C) 87

Genetic counselling for schizophrenia in the era of molecular genetics (Hodgkinson KA, Murphy J, O'Neill S, Brzustowicz L, Bassett AS) 123

Genetic insights into schizophrenia (Bassett AS, Chow EWC, Waterworth DM, Brzustowicz L) 131

Community attitudes toward people with schizophrenia (Stuart H, Arboleda-Florez J) 245

Antipsychotic polypharmacy: a survey of discharge prescriptions from a tertiary care psychiatric institution (Procyshyn RM, Kennedy NB, Tse G, Thompson B) 334

Regional cerebral glucose metabolism in never-medicated patients with schizophrenia (Clark C, Kopala L, Li DK, Hurwitz T) 340

Risperidone treatment of outpatients with schizophrenia: no evidence of sex differences in treatment response (Labelle A, Light M, Dunbar F) 534

Body mass index in persons with schizophrenia (Coodin S) 549

Social functioning in first- and multipisode schizophrenia (Grant C, Addington J, Addington D, Konner C) 746

Discourse characteristics of subjects with schizophrenia and prominent negative symptoms [letter] (Noel-Jorand MC, Giudicelli S, Dassa D) 761

The pharmacologic treatment of the early phase of first-episode psychosis in youths (Walter G, Wiltshire C, Anderson J, Storm V) 803

- Does risperidone reduce concomitant substance abuse in cases of schizophrenia? [letter] (Gupta N, Basu D) 862
- Childhood-onset schizophrenia: research update (Kumra S, Shaw M, Merka P, Nakayama E, Augustin R) 923
- schizophrénie**
- Introduction à la psychiatrie génétique : progrès vers la découverte des gènes de susceptibilité aux troubles psychiatriques (Roy M-A, Mérette C, Maziade M) 52
- Schizophrénie et psychothérapies cognitivo-comportementales (Abdel-Baki A, Nicole L) 511
- schizophrénie déficitaire**
- Le concept français d'athymhormie de 1922 à nos jours (Luauté J-P, Saladini O) 639
- school dropout**
- School dropout and conduct disorder in Brazilian elementary school students (Tramontina S, Martins S, Michalowski MB, Ketzer CR, Eizirik M, Biederman J, Rohde LA) 941
- screening instruments**
- Assessing fitness to stand trial: the utility of the fitness interview test (revised edition) (Zapf PA, Roesch R, Viljoen JL) 426
- seclusion**
- Clozapine impact on clinical outcomes and aggression in severely ill adolescents with childhood-onset schizophrenia (Chalasani L, Kant R, KN Roy Chengappa KNR) 965
- selective serotonin reuptake inhibitors**
- Olanzapine augmentation of serotonin uptake inhibitors in obsessive-compulsive disorder: an open study (Francobandiera G) 356
- Neurobiology of the use of selective serotonin reuptake inhibitors during pregnancy [letter] (Friedman EH) 371
- Neurobiology of the use of selective serotonin reuptake inhibitors during pregnancy: response [letter] (Jerome L) 452
- sensation-seeking scale**
- Factorial structure of the sensation-seeking scale-form V: confirmatory factorial analyses in nonclinical and clinical samples (Loas G, Verrier A, Flament MF, Perez-Diaz F, Corcos M, Halfon O, Lang F, Bizouard P, Venisse J-L, Guelfi JD, Jeammet P) 850
- separation anxiety disorder**
- Separation anxiety and actual separation experiences during childhood in patients with panic disorder (Bandelow B, Alvarez Tichauer GA, Späth C, Broocks A, Hajak G, MD5, Bleich S, Rüther E) 948
- serotonin**
- The neuropsychopharmacology of criminality and aggression (Lee R) 35
- Risperidone treatment of outpatients with schizophrenia: no evidence of sex differences in treatment response (Labelle A, Light M, Dunbar F) 534
- serotonin toxicity**
- Citalopram overdose, serotonin toxicity, or neuroleptic malignant syndrome? [letter] (Isbister GK, Dawson A, Whyte IM) 657
- Reply: citalopram overdose, serotonin toxicity, or neuroleptic malignant syndrome? (Aydin N, Anaç A, Çayköylü A, Akçay F) [letter] 658
- serotonin syndrome**
- Adverse reactions to St John's wort (Parker V, Wong AHC, Boon HS, Seeman MV) 77
- sex**
- Clinical guidelines for the treatment of depressive disorders [supplement] (The Canadian Psychiatric Association, Canadian Network for Mood and Anxiety Treatments) IS-92S
- Risperidone treatment of outpatients with schizophrenia: no evidence of sex differences in treatment response (Labelle A, Light M, Dunbar F) 534
- sexual abuse**
- Physical and sexual abuse issues among youths with substance use problems (Ballon BC, Courbasson CMA, Smith PD) 617
- sexual aversion disorder**
- Sexual aversion disorder treated with behavioural desensitization [letter] (Finch S) 563
- sexual desire disorders**
- The neurobiology, neuropharmacology, and pharmacological treatment of the paraphilias and compulsive sexual behaviour (Bradford JMW) 26
- sexual dysfunction**
- Antidepressant-induced sexual dysfunction in adolescent [letter] (Robinson MJ) 185
- St John's wort-induced sexual dysfunction [letter] (Bhopal JS) 456
- shared mental health care**
- Using financial incentives to promote shared mental health care (Dewa CS, Hoch JS, Goering P) 488
- side effects**
- Clinical guidelines for the treatment of depressive disorders [supplement] (The Canadian Psychiatric Association, Canadian Network for Mood and Anxiety Treatments) IS-92S
- Are newer antidepressants really "better tolerated"? [letter] (Robinson MJ) 286
- single photon emission computerized tomography**
- Neuroimaging studies of antisocial behaviour (Bassarath L) 728
- sismothérapie**
- Lignes directrices cliniques du traitement des troubles dépressifs (Association des psychiatres du Canada, Canadian Network for Mood and Anxiety Treatments) IS-92S
- sleep deprivation**
- Clinical guidelines for the treatment of depressive disorders [supplement] (The Canadian Psychiatric Association, Canadian Network for Mood and Anxiety Treatments) IS-92S
- social functioning**
- Social functioning in first- and multipisode schizophrenia (Grant C, Addington J, Addington D, Konnett C) 746
- social problem solving**
- Social functioning in first- and multipisode schizophrenia (Grant C, Addington J, Addington D, Konnett C) 746
- social support**
- Individual predictors of posttraumatic distress: a structural equation model (Regehr C, Hensworth D, Hill J) 156
- social problems**
- A social problem index for Canada (Thompson AH, Howard AW, Jin Y) 45
- socioeconomic status**
- Attention-deficit hyperactivity disorder in Manitoba children: medical diagnosis and psychostimulant treatment rates (Brownell MD, Yogendran MS) 264
- special patient populations**
- The use of electroconvulsive therapy in special patient populations (Rabheru K) 710
- specific serotonin reuptake inhibitors**
- The neurobiology, neuropharmacology, and pharmacological treatment of the paraphilias and compulsive sexual behaviour (Bradford JMW) 26
- speech**
- Using language in psychiatry (Fine J) 916
- St John's wort**
- Clinical guidelines for the treatment of depressive disorders [supplement] (The Canadian Psychiatric Association, Canadian Network for Mood and Anxiety Treatments) IS-92S
- Adverse reactions to St John's wort (Parker V, Wong AHC, Boon HS, Seeman MV) 77
- St John's wort-induced sexual dysfunction [letter] (Bhopal JS) 456
- stalking**
- Criminal harassment by patients with mental disorders (Adams SJ, Pitre NL, Smith A) 173
- statistics**
- Regression toward the mean: its etiology, diagnosis, and treatment (Streiner DL) 72
- steroids**
- Gabapentin as a prophylaxis against steroid-induced mania [letter] (Ginsberg DL, Sussman N) 455
- stigma**
- Community attitudes toward people with schizophrenia (Stuart H, Arboleda-Flórez J) 245
- Educating the public about mental illness and homelessness: a cautionary note (Tolomiczenko GS, Goering PN, Durbin JF) 253
- New century: overcoming stigma, respecting differences [presidential address] (Myers M) 907
- stimulant medication**
- Studying the epidemiology of attention-deficit hyperactivity disorder: screening method and pilot results (Rowland AS, Umbach DM, Catoe KE,

Stallone L, Long S, Rabiner D, Nafel AJ, Panke D, Faulk R, Sandler DP) 931

stimulation vagale

Lignes directrices cliniques du traitement des troubles dépressifs (Association des psychiatres du Canada, Canadian Network for Mood and Anxiety Treatments) 1S-92S

stimulation magnétique transcrânienne

Lignes directrices cliniques du traitement des troubles dépressifs (Association des psychiatres du Canada, Canadian Network for Mood and Anxiety Treatments) 1S-92S

stress disorders

Posttraumatic stress disorder, trauma exposure, and the current health of Canadian bus drivers (Vedantham K, Brunet A, Boyer R, Weiss DS, Metzler TJ, Marmar CR) 149

stroke

Psychosocial risk factors in poststroke depression: a systematic review (Ouimet MA, Primeau F, Cole MG) 819

substance abuse

Criminal harassment by patients with mental disorders (Adams SJ, Pitre NL, Smith A) 173

A profile of Canadian adults seeking treatment for gambling problems and comparisons with adults entering an alcohol treatment program (Wiebe J, Cox BJ) 418

Physical and sexual abuse issues among youths with substance use problems (Ballon BC, Courbasson CMA, Smith PD) 617

Does risperidone reduce concomitant substance abuse in cases of schizophrenia? [letter] (Gupta N, Basu D) 862

subthreshold depression

Clinical guidelines for the treatment of depressive disorders [supplement] (The Canadian Psychiatric Association, Canadian Network for Mood and Anxiety Treatments) 1S-92S

subtypes

Conduct disorder: a biopsychosocial review (Bassarath L) 609

sudden death

Sudden death following neuroleptic administration due to hemoperitoneum resulting from physical restraint [letter] (Raju GVL, Ramesh Kumar TC, Khanna S) 372

suicidal behaviour

What was the relevance of previous suicidal behaviour in prison suicides? [letter] (Fruehwald S, Eher R, Frottier P) 763

suicide

Clinical guidelines for the treatment of depressive disorders [supplement] (The Canadian Psychiatric Association, Canadian Network for Mood and Anxiety Treatments) 1S-92S

A social problem index for Canada (Thompson AH, Howard AW, Jin Y) 45

Lignes directrices cliniques du traitement des troubles dépressifs (Association des psychiatres du Canada, Canadian Network for Mood and Anxiety Treatments) 1S-92S

Lithium revisited (McIntyre RS, Mancini DA, Parikh S, Kennedy SH) 322

Suicide in adolescents in Italy (1969-1994) [letter] (Mancinelli I, Ceciarelli L, Comparelli A, Laziano S, Girardi P, Tatarelli R) 862

suicide risk

Electroconvulsive therapy's effect on suicide risk in patients with mood disorders (Sharma V) 704

supported employment

Economic impacts of supported employment for persons with severe mental illness (Latimer EA) 496

supportive-expressive therapy

Supportive-expressive group psychotherapy for inflammatory bowel disease (Mauder RG, Esplen MJ) 622

syndrome de Cotard

Électroconvulsivothérapie chez l'adolescent : considérations cliniques à propos d'une série d'observations (Étain B, Le Heuzey M-F, Mouren-Simeoni M-C) 976

syndrome malin des neuroleptiques

Électroconvulsivothérapie chez l'adolescent : considérations cliniques à propos d'une série d'observations (Étain B, Le Heuzey M-F, Mouren-Simeoni M-C) 976

T

taurine

Mania associated with an energy drink: the possible role of caffeine, taurine, and inositol [letter] (Machado-Vieira R, Viale CI, Kapczinski F) 454

teratogenicity

Lithium revisited (McIntyre RS, Mancini DA, Parikh S, Kennedy SH) 322

therapist attitudes

Alcoholism: beliefs and attitudes among Canadian alcoholism treatment practitioners (Meza EE, Cunningham JA, el-Guebaly N, Couper L) 167

tolérance

Électroconvulsivothérapie chez l'adolescent : considérations cliniques à propos d'une série d'observations (Étain B, Le Heuzey M-F, Mouren-Simeoni M-C) 976

topiramate

Accelerated weight loss after treating refractory depression with fluoxetine plus topiramate: possible mechanisms of action? [letter] (Dursun SM) 287

Tourette syndrome

Quetiapine treatment in patients with Tourette syndrome [letter] (Parraga HC, Parraga MI) 184

traitement

Schizophrénie et psychothérapies cognitivo-comportementales (Abdel-Baki A, Nicole L) 511

traitements biologiques

Lignes directrices cliniques du traitement des troubles dépressifs (Association des psychiatres du Canada, Canadian Network for Mood and Anxiety Treatments) 1S-92S

transcranial magnetic stimulation

Clinical guidelines for the treatment of depressive disorders [supplement] (The Canadian Psychiatric Association, Canadian Network for Mood and Anxiety Treatments) 1S-92S

Transcranial magnetic stimulation in the treatment of mood disorder: a review and comparison with electroconvulsive therapy (Hasey G) 720

trauma

Individual predictors of posttraumatic distress: a structural equation model (Regehr C, Hemsworth D, Hill J) 156

Attachment disorganization and dissociative symptoms in clinically treated adolescents (West M, Adam K, Spreng S, Rose S) 627

treatment

Effective interventions for children and adolescents with conduct disorder (Frick PJ) 597

Adolescents with psychiatric disorders: when to treat? And with what? [editorial] (Duffy A) 795

treatment outcome

Olanzapine augmentation of serotonin uptake inhibitors in obsessive-compulsive disorder: an open study (Francobandiera G) 356

treatment-resistant psychosis

Electroconvulsive therapy in cases of treatment-resistant psychosis [letter] (Parker V, Remington G) 762

trichotillomania

Case of resistant trichotillomania treated with risperidone-augmented fluvoxamine [letter] (Gabriel A A) 285

triglyceride

Serum lipid concentrations in patients with comorbid generalized anxiety disorder and major depressive disorder (Sevincok L, Buyukozturk A, Derboy F) 68

Antipsychotic metabolic effects: weight gain, diabetes mellitus, and lipid abnormalities (McIntyre RS, McCann SM, Kennedy SH) 273

trouble bipolaire

Introduction à la psychiatrie génétique : progrès vers la découverte des gènes de susceptibilité aux troubles psychiatriques (Roy M-A, Mérette C, Maziade M) 52

Schizophrénie et psychothérapies cognitivo-comportementales (Abdel-Baki A, Nicole L) 511

trouble dépressif

Électroconvulsivothérapie chez l'adolescent : considérations cliniques à propos d'une série d'observations (Étain B, Le Heuzey M-F, Mouren-Simeoni M-C) 976

Lignes directrices cliniques du traitement des troubles dépressifs (Association des psychiatres du Canada, Canadian Network for Mood and Anxiety Treatments) 1S-92S

trouble dépressif majeur

Lignes directrices cliniques du traitement des troubles dépressifs (Association des psychiatres du Canada, Canadian Network for Mood and Anxiety Treatments) 1S-92S

tryptophan

Tryptophan for treatment of rapid-cycling bipolar disorder comorbid with fibromyalgia [letter] (Sharma V, Barrett C) 452

22q deletion syndrome

Genetic counselling for schizophrenia in the era of molecular genetics (Hodgkinson KA, Murphy J, O'Neill S, Brzustowicz L, Bassett AS) 123
Genetic insights into schizophrenia (Bassett AS, Chow EWC, Waterworth DM, Brzustowicz L) 131

twins

Why are children in the same family so different? Nonshared environment a decade later (Plomin R, Asbury K, Dunn J) 225
Behavioural genetic perspectives on personality function (Jang KL, Vernon PA, Livesley WJ) 234

typical antipsychotic drugs

Antipsychotic drugs and obesity: is prolactin involved? (Baptista T, Lacruz A, Meza T, Contreras Q, Delgado C, Mejias MA, Hernández L) 829

U**ulcerative colitis**

Supportive-expressive group psychotherapy for inflammatory bowel disease (Mauder RG, Esplen MJ) 622

unresolved attachment

Attachment disorganization and dissociative symptoms in clinically treated adolescents (West M, Adam K, Spreng S, Rose S) 627

V**vagus nerve stimulation**

Clinical guidelines for the treatment of depressive disorders [supplement] (The Canadian Psychiatric Association, Canadian Network for Mood and Anxiety Treatments) 1S-92S

validation d'échelle

Validation de la version française du health of the nation outcome scales (HoNOS-F) (Lauzon S, Corbière M, Bonin J-P, Bonsack C, Lesage AD, Ricard N) 841

valproate

The use of intravenous valproate in psychiatry [letter] (Norton J) 371

valproic acid

The effect of divalproex sodium on viral load: a retrospective review of HIV-positive patients with manic syndromes (Maggi JD, Halman MH) 359

vanity

Vanity as a psychological construct [letter] (Bilsbury C, Roach D, Bilsbury J) 760

venlafaxine

Venlafaxine-induced hypomanic switch in bipolar depression [letter] (Gupta N) 760

video lottery terminals

Epidemiology of problem gambling in Prince Edward Island: a Canadian microcosm? (Doiron JP, Nicki RM) 413

violence

Crowding and violence on psychiatric wards: explanatory models (Kumar S, Ng B) 433

Clozapine impact on clinical outcomes and aggression in severely ill adolescents with childhood-onset schizophrenia (Chalasani L, Kant R, KN Roy Chengappa KNR) 665

vocational rehabilitation

Economic impacts of supported employment for persons with severe mental illness (Latimer EA) 496

W**weight change**

Re: weight change with antipsychotic use [letter] (Dewan VK) 660

weight gain

Antipsychotic metabolic effects: weight gain, diabetes mellitus, and lipid abnormalities (McIntyre RS, McCann SM, Kennedy SH) 273

weight loss

Accelerated weight loss after treating refractory depression with fluoxetine plus topiramate: possible mechanisms of action? [letter] (Dursun SM) 287

withdrawal

Lithium revisited (McIntyre RS, Mancini DA, Parikh S, Kennedy SH) 322

women

A prospective study of sex-specific effects of major depression on alcohol consumption (Wang J, Patten SB) 422

work characteristics

Predictors of success and satisfaction in the practice of psychiatry: a preliminary follow-up study (Garfinkel PE, Bagby RM, Schuller DR, Williams CC, Dickens SE, Dorian B) 835

Y**youth**

Physical and sexual abuse issues among youths with substance use problems (Ballon BC, Courbasson CMA, Smith PD) 617